CURRICULUM VITAE

Reza Dana
Citizenship: U.S.A.
Home Address: 406 Broadway, Cambridge, MA 02139
Work Address: -Schepens Eye Research Institute,
20 Staniford Street, Boston, MA 02114
-Massachusetts Eye & Ear Infirmary, Cornea Service,
243 Charles Street, Boston, MA 02114
Telephone: Home: (617) 661-5991
Laboratory: (617) 912-7404
Administration: (617) 912-7401
Cornea Service: (617) 573-6345
Fax Numbers: Research Office: (617) 912-0117
Clinical Admin.: (617) 573-4300
E-mail Address: dana@vision.eri.harvard.edu
Education:
1981 Diploma Summa Cum Laude, Saint Paul’s School- Concord, NH
1985 Bachelor of Arts( BA) Phi Beta Kappa, Johns Hopkins U.- Baltimore MD
1989 Master of Public Health (MPH), Johns Hopkins U.- Baltimore MD
1989 Doctor of Medicine (MD), Johns Hopkins U.- Baltimore, MD
2005 (Expec) Master of Science (MS) in Health Care Management, Harvard U.- Boston MA
Postdoctoral Training:
Internship and Residency
1989-1990 Intern in Medicine, Greater Baltimore Medical Center, Baltimore, MD
1990-1993 Resident in Ophthalmology, Illinois Eye & Ear Infirmary, Chicago, IL
Clinical and Research Fellowships
1993-1994 Fellow, Cornea & External Diseases, Wills Eye Hospital, Philadelphia, PA
1994-1995 Fellow, Immunology & Uveitis, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, MA
1994-1996 N.I.H. Research Fellow, Ocular & Transplantation Immunology, Schepens Eye Research Institute, Harvard Medical School, Boston, MA
Licensure and Certification:
1990-1993 State of Illinois medical license
1993-1994 State of Pennsylvania medical license
1994- State of Massachusetts medical license
1995- Diplomate, American Board of Ophthalmology
2003 Harvard Medical School Leadership Development for Physicians and Scientists
Academic Appointments:
1982-1984 Research Assistant, Department of Epidemiology, Johns Hopkins University School of Hygiene & Public Health.
1988-1989 Research Assistant, Ocular Immunology Laboratories, Wilmer Eye Institute, Johns Hopkins University School of Medicine.
1995-1997 Instructor, Department of Ophthalmology, Harvard Medical School.
1997-2000 Assistant Professor of Ophthalmology, Harvard Medical School.
2000- Associate Professor of Ophthalmology, Harvard Medical School.
2001- Member, Committee for Immunology, Graduate Program, Harvard Medical School.
2002- W. Clement Stone Clinical Research (Endowed) Scholar, Schepens Eye Research Institute.
Hospital & Harvard-Affiliated Institution Appointments:
1995-2002 Founder and Director, Ocular Immunology Service, Brigham & Women’s Hospital, Boston.
1995-2002 Director, Cornea and External Disease Service, Brigham & Women’s Hospital, Boston.
1995- Associate Surgeon, Department of Surgery, Brigham & Women’s Hospital, Boston.
1995-2002 Courtesy Staff, Beth Israel Deaconess Medical Center and the Joslin Diabetes Center, Boston.
1996-1997 Investigator, Schepens Eye Research Institute.
1997- Active Staff, Massachusetts Eye & Ear Infirmary, Boston.
1997- Cornea, External Disease, and Refractive Surgery Services, Massachusetts Eye & Ear Infirmary, Boston.
1997-2000 Assistant Scientist, Schepens Eye Research Institute, Boston.
2000-2004 Associate Scientist, Schepens Eye Research Institute, Boston.
2001- Associate Surgeon, Massachusetts Eye and Ear Infirmary
2004- Senior Scientist, Schepens Eye Research Institute, Boston.
Other Professional Positions and Major Visiting Appointments:
1988-1989 Principal Investigator, The Appalachia Eye Survey, Dana Center for Preventive Ophthalmology, Johns Hopkins University School of Medicine, Baltimore.
1992-1997 Principal Investigator, Multicenter Pediatric Keratoplasty Study Group.
1995-1996 Consultant in ocular immunology, Alza Corporation, Palo Alto, CA.
1995-2002 Principal Investigator, Multicenter Quality-of-Life and Psychometric Analysis after Corneal Transplantation (Q-PACT) Study.
1996-1998 Member, CNS Lupus Study Group, Departments of Rheumatology, Ophthalmology, Neurology, Psychiatry, Endocrinology, and Neuroradiology, Brigham and Women’s Hospital.
1998- Consultant in cornea and ocular surface disease, Allergan Corporation, Irvine, CA.
1998- Consultant in ocular immunology, Biogen, Cambridge, MA.
1999-2000 Consultant in ophthalmology and anterior segment surgery, Becton Dickinson Ophthalmic Systems, Waltham, MA.
2000- Consultant in cornea and ocular surface diseases, Daiichi Pharmaceutical Corporation, Montvale, NJ.
2000 Visiting Professor, Department of Ophthalmology, Federal University of S. Paolo, Paulista School of Medicine, Sao Paulo, Brazil (December, 2000)
2001-2002 Consultant in corneal diseases and ocular immunology, Santen, Napa, CA.
2001-2002 Consultant in cornea and ocular surface diseases, Alcon Pharmaceuticals, Fort Worth, TX
2001- Member, Harvard Medical School Committee for Immunology
2001-2002 Consultant in ocular immunology, Vertex Pharmaceuticals, Cambridge, MA.
2002- Visual Sciences A Study Section, National Eye Institute, National Institutes of Health
2002- Consultant in corneal and ocular surface diseases, Pfizer, New Jersey.
2002- Member, Advisory Board, Women’s Eye Health Task Force
2003- Consultant in ocular immunology, Genentech, San Francisco, CA
2003- Consultant in immunology, Isotis, Lausanne, Switzerland
2003- Consultant in cornea and ocular surface diseases, Alcon Pharmaceuticals, Fort Worth, TX
Hospital Service Responsibilities
1995-2002 Director, Cornea/External Disease and Ocular Immunology Services, Brigham and Women’s Hospital.
1996-1998 Director, Massachusetts Eye & Ear Infirmary Ophthalmology Residency Training at Brigham and Women’s Hospital.
1998-2003 Director, Anterior Segment Fellowship Program, Brigham & Women’s Hospital and Massachusetts Eye & Ear Infirmary.
1997- Member, Cornea / External Disease and Refractive Surgery Service, Massachusetts Eye & Ear Infirmary and Brigham & Women’s Hospital.

Major Administrative Responsibilities
1998-1999 Conference Chair, Boston Symposium on Sjogren’s Syndrome and Allied Disorders.
1999-2000 Organization and Program Committee, Third International Conference on the Lacrimal Gland, Tear Film, and Dry Eye Syndromes.
1999- Medical Advisory Board, National Sjogren’s Syndrome Association, Cleveland, OH.
2001-2002 Conference Co-Chair, First International Workshop on Corneal Immunology, Bermuda
2001- Medical and Scientific Advisory Board, Sjogren’s Syndrome Foundation, New York, NY
2001-2003 Scientific Advisory Board, Wadsworth Foundation for Multiple Sclerosis Research, Seattle, WA
2001- Medical and Scientific Advisory Board, Tear Film and Ocular Surface Society, Boston, MA
2002- Chair, Membership Committee; and Member, Executive Committee, American Uveitis Society, New Orleans, LA
Major Committee Assignments:
Schepens Eye Research Institute-
1995-1996 Member: Clinical Advisory Committee of the Board of Trustees
1995- Member: Immunity, Inflammation, and Transplantation Focus Group
1997 Member: Steering Committee, Clinical Research Studies Center
1997-2000 Member: Training Committee
1997- Member: Technology Transfer Committee
1997-2000 Member: Responsible Conduct of Research Committee
1997-1999 Member: Seminars Committee
1998-2000 Head: Dry Eye Research Program
1999- Member: Human Research Committee
1999- Member: Subcommittee for Clinical Research Strategic Planning
1999-2000 Co-Chair: Anterior Segment Program of SERI Fiftieth Anniversary
1999- Member: Executive Committee, Center for Research on the Aging Eye
2000-2001 Member: Subcommittee for development of new faculty track for appointments and promotions
2000-2002 Head: Center for Development of Ophthalmic Therapeutics and Devices Subcommittee
2000- Head: Corneal Transplantation Research Program
2000- Member: Research Planning and Review Committee
2001- Chair: Human Research Committee-IRB

Massachusetts Eye and Ear Infirmary
2001-2004 Surgical Case Review Committee
2004- Eye and ENT Pharmacy Committee

Department of Ophthalmology, Harvard Medical School-
1996-1997 Member, Organizing Committee, Harvard Department of Ophthalmology Biennial Cornea Research Conference
1998 Member, Faculty Search Committee, Low Vision Rehabilitation Research
1999- Founding Member, Scientific Center Utilization Review Committee, Harvard Department of Ophthalmology Joint Clinical Research Center
2000- Faculty Member, Harvard Department of Ophthalmology/National Eye Institute Training Grant program
2000- Co-Chair, Harvard Department of Ophthalmology Biennial Cornea Research Conferences
2000- Member and Faculty Course Coordinator (2003æ), Curriculum Committee, NIH/NEI Training Program in the Molecular Bases of Eye Diseases, Harvard Department of Ophthalmology
2002- Member, Predoctoral Training Grant in Immunology, Harvard Medical School
2003- Course director and organizer, Neurobiology 300, “Biology of Ophthalmic Diseases”


National & International-
2000- Member, Food and Drug Administration (FDA) Orphan Drug Development Advisory Panel
2001-2002 Conference Chair and Organizer, First International Workshop on Corneal Immunology, Bermuda, 2002
2000- Ad hoc reviewer, Wellcome Trust grants, United Kingdom
2001- Ad hoc reviewer, Israel Science Foundation grants
2002- Permanent member, Visual Sciences A Study Section, National Eye Institute, National Institutes of Health

Professional Societies:

1987-1990; 1995- American Medical Association
1988- Association for Research in Vision and Ophthalmology
1990- Johns Hopkins Medical and Surgical Association
1992- American Academy of Ophthalmology
1993-1996 Contact Lens Association of Ophthalmologists
1993-1996 American Society of Cataract and Refractive Surgery
1994-1997 Pediatric Keratoplasty Association
1994- Ocular Microbiology and Immunology Group
1994- Wills Eye Hospital Association
1994- Massachusetts Society of Eye Physicians & Surgeons
1995- Society of Heed Fellows
1995- American Uveitis Society (Executive Committee since 2002)
1996- Massachusetts Medical Society
1996- Cornea and External Disease Academic Society
1996- International Ocular Inflammation Society
1997- Castroviejo Cornea Society
1998- Transplantation Society
1998- New England Ophthalmological Society
1998- American Association of Immunologists
1999- Medical Advisory Board, National Sjogren’s Syndrome Association
2000- Medical and Scientific Advisory Board, Sjogren’s Syndrome Foundation
2000- American Association for the Advancement of Science
2000- Paton Society, Eye Bank Association of America
Editorial Activities:
1994- Reviewer for New England Journal of Medicine, Journal of Immunology, Investigative Ophthalmology and Visual Science, Nature Reviews Drug Discovery, Journal of Clinical Investigation, American Journal of Pathology, Experimental Eye Research, Transplantation, Microbes and Infection, Archives of Ophthalmology, American Journal of Ophthalmology, Cornea, Ophthalmology, Refractive Surgery, British Journal of Ophthalmology, Annals of Internal Medicine, Journal of Leukocyte Biology, Ocular Immunology and Inflammation, Laboratory Investigation, Journal of Interferon and Cytokine Research
2001- Guest Editorial Board Member, Investigative Ophthalmology and Visual Science
2002- Editorial Board Member, Cornea, The Ocular Surface
Awards and Honors:
1981 National Cum Laude Society
1984 Alpha Epsilon Delta International Premedical Honor Society
1984 Phi Beta Kappa (Junior Year), Johns Hopkins University
1981-1985 Dean's List (every semester), Johns Hopkins University (GPA 3.96)
1985 Diplomate of BA with General Honors, Johns Hopkins University
1989 Henry Strong Dennison Award for Research, Johns Hopkins University School of Medicine
1990 NEI/Association for Research in Vision and Ophthalmology Travel Fellowship
1995 Heed Ophthalmic Foundation Fellowship (Ocular Immunology)
1996 Named Fellow of the Society of Heed Fellows (Special Recognition Award)
1996 Clinical Scientist Career Award (NIH)
1999 Invited Participant, Research to Prevent Blindness National Science Writers Seminar
1999 Research to Prevent Blindness William & Mary Greve Scholar
(RPB Special Scholar Award)
2000 Second Decade (alumni honor) Society, Johns Hopkins University
2002 Achievement Award, American Academy of Ophthalmology
2002 Krill Memorial Lecturer, Illinois Eye & Ear Infirmary
2002 Fry Memorial Lecturer, Wills Eye Hospital Biennial Cornea Conference
2003 Cogan Award, Association for Research In Vision and Ophthalmology
2003 Dohlman Lecturer, Biennial Cornea Conference, Harvard Dept. of Ophthalmology
2003 Listed in “Guide to America’s Top Ophthalmologists”- Consumers’ Research Council of America
2004 Alta Lecturer and visiting professorship, University of California in San Francisco (UCSF)
2004 Keynote Speaker, 28th Japan Cornea Conference, Yonago, JapanRESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS
Research Funding Information:
Past: 1988-1989 Fight For Sight Research Division of the National Society to Prevent Blindness Student Research Fellowship: PI
Development of a community-based survey of blindness in rural North America/Appalachia region.
1988-1989 Research Grant from the Eleanor Naylor Dana Charitable Trust, Wilmer Eye Institute, Johns Hopkins School of Medicine: PI
Prevalence and causes of blindness and visual impairment in an Appalachian river valley
1992-1993 Illinois Society for the Prevention of Blindness Research Grant: PI
Dynamic shifts in corneal topography after radial and astigmatic keratotomy
1995-1996 Individual National Research Service Award, NEI/NIH: PI
Corneal neovascularization and the immunobiology of high-risk penetrating keratoplasty
1995-1996 Eye Bank Association of America Research Grant: PI
Role of corneal lymphangiogenesis in high-risk transplantation
1996-1997 Eye Bank Association of America Research Grant: Co-Investigator
Development of new photodynamic glue for corneal applications
1996-1997 Massachusetts Lions Eye Research Fund: Co-PI
New strategies for controlling ocular inflammation
1997-1998 SERI Institutional Research Grant: Co-PI
Cytokine modulation in atopic eye disease
1998-1999 Fight For Sight / Prevent Blindness America Grant-in-Aid: PI
Role of IL-1ra in T cell responses in high-risk corneal transplantation
1998-1999 SERI Institutional Research Grant: Co-PI
Host T cell responses in corneal transplantation
1998-1999 Eye Bank Association of America (EBAA) Research Award: PI
Topical modulation of IL-1 activity in corneal allotransplantation
1996-2000 NEI/NIH K08 Clinical Scientist Development Award: PI
Immunobiology of high-risk corneal transplantation
1997-2000 Sponsored Research Program Recipient, Amgen: PI
Proinflammatory cytokines in corneal inflammation and transplantation immunology
1999-2000 Research Support Agreement, Alcon: PI
Long-term efficacy and tolerability of silicone punctal occlusion in Sjogren’s and dry eye syndromes
1999-2000 Research to Prevent Blindness William and Mary Greve Special Scholar Award: PI
Cytokine modulation in corneal transplantation
1999-2000 Research Grant, Harvard Department of Ophthalmology Joint Clinical Research Center: Co-PI
Harvard Dry Eye Epidemiology Study
1999-2000 Massachusetts Lions Eye Research Fund: Co-PI
Promotion of transplant survival without generalized immunosuppression
2000-2001 Research Grant, Harvard Department of Ophthalmology Joint Clinical Research Center: Co-PI
Measurement of tear mucin levels in dry eye and allergic conjunctivitis patients
2001-2002 Eye Bank Association of America (EBAA) Research Award: PI
Use of antiapoptotic gene therapy for promotion of corneal transplant survival
2001-2003 Roche Organ Transplantation Research Fund: PI
Promotion of corneal graft survival by anti-apoptotic genes
2002-2003 Department of Defense: PI
Gene therapy for donor corneal storage and prolonging graft survival
Current: 2000-2005 NEI/NIH R01-EY12963: PI
Mechanisms of sensitization in high-risk corneal grafts
1998- Sponsored Research Program Recipient, Biogen: PI
Regulation of ocular immunity and inflammation
2001- Sponsored Research Program Recipient, Allergan: PI
Ocular surface inflammation and immunity in dry eye syndromes
2001- Sponsored Research Program Recipient, Daiichi: PI
Multicenter Study for development of global index of symptomatology in dry eye syndrome
2000-2004 NEI/NIH R01: Co-investigator (PI: Dr. Wayne Streilein)
Immunobiology of Corneal Transplantation
2000-2004 NEI/NIH R01: Co-investigator (PI: Dr. Ilene Gipson)
Ocular surface mucins
2003-2007 NEI/NIH R01: Co-investigator (PI: Dr. Pablo Argueso)
O-Glycans on mucins of the ocular surface
2001-2006 NEI/NIH Program Training Grant: Faculty
Molecular Bases of Eye Disease
2003-2004 Eye Bank Association of America (EBAA) Research Award: PI
Promotion of corneal transplant survival by integrin-based immunotherapy
2003-2004 Department of Defense: PI
Prevention of apoptotic cell death in cornea as result of injury and inflammation
2004-2005 Research Grant, Harvard Department of Ophthalmology Joint Clinical Research Center: Co-PI
Role of toll-like receptors (TLR) in innate immune response in dry eye syyndromes
Pending: 2004-2006 NIH R21: PI
Regulation of corneal apoptosis in corneal transplantation
Report Of Teaching:
1. Local Contributions
a. Harvard Medical School
1996-1998 Medical Student Ophthalmology and Emergency Medicine Rotation
Instructor: Ophthalmoscopy, biomicroscopy, and other basic procedures and concepts
5 medical students (per section); 2 medical students (clinic rotation)
3 hours/year (as practical section leader); 20-30 hours/year (as clinic attending)

2000- Instructor, Inflammatory and Immune-mediated ocular diseases
Training Program in the Molecular Bases of Eye Diseases, Harvard Department of Ophthalmology
2002 Course Co-Director, Harvard Medical International Master Workshop in Design and Conduct of Clinical Research, U. Tokyo, Tokyo, Japan

2003- Tutorial Instructor, Immunology, Microbiology and Infectious Diseases Course (IN704.0)
Harvard Medical School

2003- Course Organizer and Instructor, Biology of Ophthalmic Diseases (Neurobiology 300)
Harvard Medical School
b. Graduate Medical Courses and Presentations
1995 Immunology Seminar, Mass. Eye & Ear Infirmary
“Corneal angiogenesis: cellular and molecular aspects”
15-20 residents, fellows, and staff
30 hours preparation; 1 hour lecture
1995-1996 Ophthalmology Lecture Series
Course Director: Biweekly didactic seminars for Longwood Medical Area fellows and Massachusetts Eye & Ear Infirmary residents
4 fellows and 8 ophthalmology residents/year
40 hours/year preparation; 10 hours as lecturer

1997 Cornea Conference, Mass. Eye & Ear Infirmary
“Autoimmunity in Sjogren’s and dry eye syndromes”
20-30 residents, fellows, and staff
4 hours preparation; 1 hour lecture
Brigham and Women’s Primary Care Medicine Conference
“Guidelines for management of ocular and adnexal infectious diseases”
15 residents and faculty
2 hours preparation; 1 hour lecture
Research Seminar, Schepens Eye Research Institute
“Cytokine modulation in corneal inflammation and ocular immune privilege”
50 fellows and faculty
3 hours preparation; 1 hour lecture
1998 Cornea Conference, Mass. Eye & Ear Infirmary
“Corneal transplantation immunology”
40-50 residents and fellows
2 hours preparation; 1 hour lecture
Research Seminar, Schepens Eye Research Institute
“Interleukin-1 and tumor necrosis-alpha in corneal inflammatory disease: Regulation of adhesion molecules and alloimmune responses”
50-60 fellows and faculty
8 hours preparation; 1 hour lecture
Allergy and Immunology Conference, Children’s Hospital
“Immunology of ocular atopic disorders”
15 residents, fellows, and faculty
3 hours preparation; 1 hour lecture
Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Immunopathogenesis of Sjogren’s syndrome”
20-30 residents, fellows, and staff
4 hours preparation; 1 hour lecture
1999 Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Ocular surface inflammatory disorders”
40 residents, fellows, and staff
2 hours preparation; 1 hour lecture
Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Molecular and cellular mechanisms of alloimmunity in corneal transplantation”
40 residents, fellows, and staff
1 hour preparation; 1 hour lecture
Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Immunology of high-risk corneal transplantation”
30 residents, fellows, and staff
5 hours preparation; 1 hour lecture
Research Seminar, Schepens Eye Research Institute
“Molecular and cellular mechanisms of allosensitization in corneal transplantation”
50 fellows and staff
4 hours preparation; 1 hour lecture
2000 Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Sjogren’s syndrome: Diagnosis, pathophysiology, and treatment”
40 residents, fellows, and staff
2 hours preparation; 1 hour lecture
Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Current issues in pediatric keratoplasty”
30 residents, fellows, and staff
1 hour preparation; 1 hour lecture
Research Seminar, Schepens Eye Research Institute
“Role of proinflammatory cytokines and cytokine receptors in corneal transplantation”
40 fellows and staff
6 hours preparation; 1 hour lecture
2001 Research Seminar, Schepens Eye Research Institute
“Novel facets of antigen-presenting cell distribution and trafficking in the cornea”
50 fellows and staff
3 hours preparation; 1 hour lecture
Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Immunology of corneal transplantation”
30 residents, fellows, and staff
1 hour preparation; 1 hour lecture
2002 Research Seminar, Schepens Eye Research Institute
“Role of proinflammatory cytokines and cytokine receptors in corneal transplantation”
40 fellows and staff
6 hours preparation; 1 hour lecture
Advanced Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Pathogenesis, classification, and treatment of chronic ocular surface disease in dry eyes”
30 residents, fellows, and staff
3 hours preparation; 1 hour lecture
2003 Research Seminar, Schepens Eye Research Institute
“Why corneal grafts reject”
40 fellows and staff
6 hours preparation; 1 hour lecture
Resident Lecture Series, Mass. Eye & Ear Infirmary
“Use of systemic immunosuppressives in corneal and scleral diseases”
30 residents and staff
1 hours preparation; 1 hour lecture
Cornea Lecture Series, Mass. Eye & Ear Infirmary
“Immunopathogenesis of corneal transplant rejection”
50 fellows, residents, and staff
2 hours preparation; 1 hour lecture
2004 Ocular Gene Therapy Program Research Seminar, Schepens Eye Research Institute
“Applications of gene therapy technologies to corneal transplantation”
20 fellows and staff
4 hours preparation; 1 hour lecture
c. Invited Presentations
1995 Longwood Medical Area Ophthalmology Grand Rounds
“Challenges in outcomes assessment in pediatric keratoplasty”
30-40 residents, fellows, and faculty
5 hours preparation; 1 hour lecture
Grand Rounds, Brigham and Women’s Division of Rheumatology
“Ocular manifestations of systemic immune-mediated disease”
30 residents, fellows, and faculty
3 hours preparation; 1 hour lecture
1996 Brigham and Women’s Allergy and Immunology Conference
“Immunopathogenesis of ocular allergic disorders”
10 residents, fellows, and faculty
5 hours preparation; 1 hour lecture
1997 Grand Rounds, Mass. Eye & Ear Infirmary
“Cytokine modulation in corneal transplantation and inflammation”
40-50 residents, fellows, and faculty
10 hours preparation; 1 hour lecture
Grand Rounds, Brigham and Women’s Division of Rheumatology, Immunology, and Allergy
“Sjögren’s and autoimmune sicca syndromes”
30 residents, fellows, and faculty
2 hours preparation; 1 hour lecture

1998 Research Conference, BWH Center for Ophthalmic Research
“Cytokine regulation in corneal allosensitization”
10 fellows and faculty
3 hours preparation; 1 hour lecture
Longwood Medical Area Ophthalmology Grand Rounds
“Cytokines in corneal inflammation and immunity”
20 residents, fellows, and faculty
4 hours preparation; 1 hour lecture
1999 Grand Rounds, Brigham and Women’s Division of Rheumatology, Immunology, and Allergy
“Ocular Inflammation in patients with rheumatic diseases”
30 residents, fellows, and faculty
2 hours preparation; 1 hour lecture
Grand Rounds, Mass. General Hospital Department of Medicine, Rheumatology Unit
“Ophthalmic manifestations of systemic rheumatic diseases”
20 residents, fellows, and faculty
3 hours preparation; 1 hour lecture
2000 Grand Rounds, Brigham and Women’s Division of Rheumatology, Immunology, and Allergy
“The spectrum of ocular manifestations in systemic immune disorders”
2001 Invited Speaker, Tufts University Department of Ophthalmology Research Conference, Boston, MA
“Emerging concepts in the cellular and molecular basis of corneal alloimmunity”
30 residents, fellows, and faculty
2 hours preparation; 1 hour lecture
Invited Speaker, Wellman Laboratory for Photomedicine, Mass. General Hospital, Boston, MA
“Immune modulation in corneal and ocular surface inflammation and immunity”
20 residents, fellows, and faculty
3 hours preparation; 1 hour lecture

2002 Invited Speaker, Transplantation Biology Research Center, Mass. General Hospital, Boston, MA
“Allosensitization in corneal transplantation”
30 fellows, faculty, and staff
2 hours presentation; 1 hour lecture

2003 Co-Chair, First Harvard-wide Workshop on Cell Death & the Eye, Massachusetts Eye & Ear Infirmary
35 faculty and PI’s
1 full day
2004 Grand Rounds, Brigham and Women’s Division of Rheumatology, Immunology, and Allergy
“Ocular immune responses in patients with systemic rheumatic diseases”
30 residents, fellows, and faculty
3 hours preparation; 1 hour lecture
d. CME Courses sponsored by Harvard Medical School
1996-2001 Intensive Review of Infectious Diseases
- Instructor: “Ocular infectious disease diagnosis and management”
- 100-200 physicians/year
- 30 hours preparation first year; 1 hour/year after that
- 1 hour lecture
1997 Harvard Medical School Postgraduate Rheumatology Course, “Advances in Rheumatology”
Instructor: “Ocular manifestations of Rheumatic Diseases”
80-100 residents and fellows
10 hours preparation; 1 hour lecture
1998 Intensive Review of Adult and Pediatric Allergy and Immunology, (cosponsored by the American Academy of Allergy, Asthma, and Immunology and Mass. General Hospital)
- Instructor, “Immunopathology of eye diseases; review of cellular and molecular mechanisms of immunity and inflammation in the eye”
- 7 hours preparation; 1 hour lecture
1998- Intensive Review of Ophthalmology
- Principal Instructor for Cornea and External Diseases (1998-), and Immunology and Uveitis (1999-) sections
- 100-200 physicians/year
- 100 hours preparation first year; 5 hours/year after that
- 5 hours lecture/year
2001- Lancaster Course in Ophthalmology
- Instructor for Cornea and External Diseases
- 100-200 physicians/year
- 4 hours preparation
- 3 hours lecture/year
e. Supervisory and Advisory Responsibilities

1995- Postdoctoral Fellow Advisor
2-6 clinical fellows (cornea and anterior segment services)/year
2 fellows in clinical immunology and allergy/year
2-5 laboratory research fellows and predoctoral students (immunology)/yr
1996-1997 Joint Harvard-Affiliated Program in Emergency Medicine
- Instructor: Essential concepts in care of corneal and external disease emergencies for ER residents
- 6-8 residents/year
- 50-100 hours/year (as clinic attending)
1996- Immunology Fellowship Program
- Teaching diagnosis and management of ocular inflammatory diseases to Allergy and Immunology (Department of Medicine) fellows rotating through Cornea & Ocular Immunology clinics
- 2 fellows/year
- 100-150 hours/year (as clinic attending)
1997-1998 BWH Primary Care Ophthalmology Rotation
- Instructor: Essential concepts in primary care ophthalmology
- 3-4 residents/year
- 30-40 hours/year (as clinic attending)
1997- Undergraduate Student Advisor, Harvard College
Tutor: Currier House
f. Teaching Leadership Roles
1994-1995 Immunology Seminar Series, Mass. Eye & Ear Infirmary
- Organizer
- 8 clinical and research fellows and 10-25 staff members
- 40 hours/year

1995- Anterior Segment Fellowship, combined BWH-MEEI program
- Instructor and Co-Director (1995-1998); Director (1999- ): supervise fellow and resident activities in the clinic and operating rooms; mentor research projects
- 2 fellows (BWH) and 6 residents (MEEI)/year
- 300-400 hours/year
1997- Cornea Service Attending, Mass. Eye & Ear Infirmary
- Instructor: surgical and clinical care of patients with corneal and anterior segment disease; mentored research projects
- 5-6 fellows/year
- 300 hours/year
1999- Board Review of Ophthalmology for Residents and Fellows
- Instructor for Cornea/External and Inflammatory Diseases
- 30 MEEI and affiliated institutions residents and fellows
- 3-4 hours lecture/year
2000- Harvard Dept. of Ophthalmology/National Eye Institute Training Grant Program
- Instructor for ocular immunology, “Biology of Ophthalmic Disease”
- Course coordinator (2003- )
g. Names of Mentored Trainees / Research Program / Current Position
1996-2001 Mini Balaram, MD, Postdoctoral Fellow, “Ocular surface inflammatory diseases”. Currently Staff Ophthalmologist, Madurai, India
1996-1998 Suning Zhu, MD, PhD, Postdoctoral Research Fellow, “Cytokine regulation of adhesion factors in corneal inflammation and immunity”. Currently Senior Research Associate, University of Toronto Dept. of Pathology, Canada
1997-1998 Iva Dekaris, MD, PhD candidate, “Molecular mechanisms of antigen-presenting cell motility in the cornea and ocular surface”. Currently Chair, University of Zaghreb Dept. of Ophthalmology and Croatia Lions Eye Bank, Croatia
1998-1999 Satoru Yamagami, MD, PhD, Postdoctoral Research Fellow, “Chemokine gene expression in corneal transplantation and inflammation”. Currently Associate Professor of Ophthalmology, Jichi Medical School, Tokyo, Japan
1998-2001 Ying Liu, MD, PhD, Postdoctoral Research Fellow, “Induction of immunity to intracorneal antigens”, Schepens Eye Research Institute, Boston, MA. Currently Research Associate, Schepens Eye Research Institute, Boston, MA.
1998-2002 Ying Qian, MD, PhD, Postdoctoral Research Fellow, “Role of TNF superfamily receptors in corneal immunity”, Currently Resident in Ophthalmology, University of Rochester, Rochester, NY
1999-2001 Pedram Hamrah, MD, Postdoctoral Research Fellow, “Corneal antigen-presenting cell function and activation”, Schepens Eye Research Institute, Boston, MA. Currently Resident in Ophthalmology, University of Louisville, Louisville, KY
1999-2001 Vikas Tewari, Predoctoral student (Brown U), “Ocular inflammatory diseases”. Currently Resident in Ophthalmology, Wills Eye Hospital, Philadelphia, PA
2000-2002 Sudhir Vora, Predoctoral student in Pasteur Research Program (Harvard), “Patterns of chemokine expression in ocular inflammatory diseases”. Currently Student at Harvard Medical School, Boston, MA
2001-2002 Flavia Mendes, MD, Postdoctoral Research Fellow, “Outcome measures in anterior segment diseases”, Brigham and Women’s Hospital and Schepens Eye Research Institute, Boston, MA
2001-2003 Clay Beauregard, PhD, Postdoctoral Research Fellow, “Role of caspases in inflammation and apoptosis in the cornea”, Schepens Eye Research Institute, Boston, MA
2002-2003 Komal Trivedi, MD, Postdoctoral Research Fellow, “Risk factors for pathogenesis of chronic ocular surface disease”. Currently fellow in Laboratory of Dr. Darlene Dartt, Schepens Eye Research Institute and Brigham and Women’s Hospital, Boston, MA
2002-2004 Claus Cursiefen, MD (Co-mentor), Postdoctoral Research Fellow, “Molecular regulation of angiogenesis and lymphangiogenesis in the cornea”, Schepens Eye Research Institute, Boston, MA
2001-2003 Clay Beauregard, PhD, Postdoctoral Research Fellow, “Role of caspases in inflammation and apoptosis in the cornea”, Schepens Eye Research Institute, Boston, MA
2001- Lu Chen, PhD, “Corneal dendritic cell trafficking”. Postdoctoral Research Fellow, Schepens Eye Research Institute, Boston, MA
2001- Syed Huq, MD, Postdoctoral Research Fellow, “Pathways of allosensitization in corneal transplantation”, Schepens Eye Research Institute, Boston, MA
2001- Abha Sood, MD, Postdoctoral Research Fellow, “Immunopathogenesis of ocular surface disease in dry eye syndrome”, Schepens Eye Research Institute, Boston, MA
2003- LinLing Shen, PhD, Postdoctoral Research Fellow, “Induction of tolerance by corneal dendritic cells”, Schepens Eye Research Institute and Brigham and Women’s Hospital, Boston, MA
2003- Stefano Barabino, Doctoral student, University of Genova, Italy
“Molecular and cellular immunopathogenesis of dry eye syndromes”, Schepens Eye Research Institute and and Mass. Eye & Ear Infirmary, Boston, MA
2003- William Chen, Postdoctoral fellow, “Role of toll-like receptors in activation and function of corneal dendritic cells”, Schepens Eye Research Institute and Mass. Eye & Ear Infirmary, Boston, MA
2. Regional, National, and International Presentations & Contributions
1989 Wilmer Eye Residents’ Association Annual Conference, Johns Hopkins University, Baltimore, MD
“The Appalachia Eye Survey”
ARVO Annual Meeting, Sarasota, FL
“Visual impairment in rural Appalachia”
1990 ARVO Annual Meeting, Sarasota, FL
“UV-B Treatment of corneal endothelium and graft survival”
1991 ARVO Annual Meeting, Sarasota, FL
“Contact lens failure in keratoconus management”
1992 Annual Chicago Clinical Challenges Day, Chicago, IL
“Ectodermal dysplasia and the EEC syndrome”
ARVO Annual Meeting, Sarasota, FL
“The epidemiology, causes and prognosis of vitreous hemorrhage”
1993 Annual Chicago Clinical Challenges Day, Chicago, IL
“Necrotizing sclerokeratitis after pterygium surgery”
ARVO Annual Meeting, Sarasota, FL
“Ocular manifestations of Hansen's Disease (leprosy) in the U.S.”
1994 The Wills Eye Hospital & Pennsylvania Academy of Ophthalmology Combined Annual Meeting, Philadelphia, PA
“Suture erosion after penetrating keratoplasty”
ARVO Annual Meeting, Sarasota, FL
“Risk factors for suture erosion after penetrating keratoplasty”
Annual Meeting of the American Academy of Ophthalmology,
San Francisco, CA
“The Multicenter Pediatric Keratoplasty Study: Indications & outcomes”
Wills Eye Hospital Biennial Cornea Conference, Philadelphia, PA
“What have we learned from the Multicenter Pediatric Keratoplasty Study?”
1995 Second New England Immune Regulation & Privileged Sites Meeting, Boston, MA
“Induction of ACAID to herpes simplex virus-1 antigens”
ARVO Annual Meeting, Ft. Lauderdale, FL
“Outcome of penetrating keratoplasty for ocular trauma in children”
Third New England Immune Regulation & Privileged Sites Meeting, Brown University, Providence, RI
“Loss of immune privilege in murine corneas cannot be explained by corneal lymphangiogenesis alone”
Annual Meeting of the American Uveitis Society, Atlanta, GA
“Outcomes analysis in Juvenile Rheumatoid Arthritis-associated uveitis”
Annual Meeting of the American Academy of Ophthalmology, Atlanta, GA
“Outcomes analysis in ocular sarcoidosis”
Annual Meeting of the Ocular Microbiology and Immunology Group, Atlanta, GA
“Uveitis in Juvenile Rheumatoid Arthritis”
1996 Fourth New England Immune Regulation & Privileged Sites Meeting, University of Connecticut, Farmington, CT
“Loss and restoration of immune privilege in neovascularized corneas”
ARVO Annual Meeting, Ft. Lauderdale, FL
“The Role of lymphangiogenesis and infiltrating Langerhans cells in the loss of immune privilege in the eye”
Annual Meeting of the American Academy of Ophthalmology, Chicago, IL
“Posterior capsule opacification after cataract surgery in uveitis patients”
Annual Meeting of the American Academy of Ophthalmology, Chicago, IL
“Corneal transplantation in children for mesenchymal dysgeneses. Results from the Multicenter Pediatric Keratoplasty Study”
Wills Eye Hospital Biennial Cornea Conference, Philadelphia, PA
“Corneal transplantation in infants with mesenchymal dysgenesis”
1997 ARVO Annual Meeting, Ft. Lauderdale, MA
“Topical interleukin-1 receptor antagonist (IL-1ra) suppresses Langerhans cell activity and promotes immune privilege”
Invited Speaker, Biogen, Cambridge, MA
“Cytokines and ocular immunity: studies in corneal transplantation”
Invited Speaker, Twentieth Biennial Harvard Cornea Research Conference, Boston, MA
“Corneal Neovascularization: Cytokine regulation and implications for ocular immunity”
Invited Speaker, Amgen, Boulder, CO
“Cytokine modulation in ocular inflammation and transplantation”
Annual Meeting of the American Academy of Ophthalmology, San Francisco, CA
“Ocular surface disease after allogeneic bone marrow transplantation”

Annual Meeting of the Ocular Microbiology and Immunology Group, San Francisco, CA
“Promotion of corneal transplant survival by interleukin-1 receptor antagonist is mediated by suppression of Langerhans cell activity and allosensitization”
Annual Meeting of the Castroviejo Cornea Society, San Francisco, CA
“Topical modulation of interleukin-1 activity in corneal inflammatory neovascularization”
Invited Speaker, Grand Rounds, Dept. of Medicine, NYU Medical School, New York
“Ophthalmic manifestations of systemic immune mediated disorders”
1998 Invited Speaker, Lupus Foundation of America, Massachusetts Chapter.
“Lupus and the Eyes”
Invited Speaker, Loma Linda University Department of Ophthalmology, Loma Linda, California
“Indications, challenges, and outcomes in pediatric corneal transplantation”
ARVO Annual Meeting, Ft. Lauderdale, FL
“Role of TNF-a receptors I and II activity in corneal allotransplantation and post-keratoplasty neovascularization”
First Combined International Symposium on Ocular Immunology and Inflammation, Amsterdam
“Role of TNF-a receptors in corneal transplantation immunology”
Annual Meeting of the Ocular Microbiology and Immunology Group, New Orleans, LA
“Interleukin-1 receptor antagonist does not promote corneal transplant survival in allosensitized hosts”
Annual Meeting of the Castroviejo Cornea Society, New Orleans, LA
“Soluble tumor necrosis factor-alpha receptor I (sTNFRI) inhibits corneal Langerhans cell migration”
Invited Speaker, Eighth Iranian Congress of Ophthalmology, Tehran
“Corneal transplantation in young children”
Invited Speaker, Eighth Iranian Congress of Ophthalmology, Tehran
“Systemic immune modulation in inflammatory eye diseases”
Invited Speaker, Eighth Iranian Congress of Ophthalmology, Tehran
“Immunobiology of corneal transplantation: how far have we come in five
decades?”
Invited Speaker, Eighth Iranian Congress of Ophthalmology, Tehran
“Sjögren’s and autoimmune ocular surface diseases”
1999 Invited Speaker, New England Ophthalmological Society, Boston
“Immunology of high-risk corneal transplantation”
Speaker, Symposium on Sjogren’s and Allied Disorders, Boston
“Sjogren’s and dry eye syndromes: Disease spectrum and classification”
Invited Speaker, Biogen, Cambridge, MA
“New developments in treatment of ocular inflammatory disease: the CD40-CD154 costimulatory pathway”
Invited Participant, Workshop on the Meibomian Gland and its Diseases, Coral Gables, FL
Invited Speaker, Amgen, Thousand Oaks, CA
“Cytokine modulation in eye disease”
Invited Speaker, Twenty-First Biennial Cornea Research Conference, Boston, MA
“Modulation of the local cytokine microenvironment in corneal allotransplantation and inflammation”
Invited Speaker, Research to Prevent Blindness National Science Writers Seminar, Los Angeles, CA
“Enhancing corneal graft survival: Exploiting the cytokine network”
Invited Speaker, Allergan, Irvine, CA
“The cytokine network in corneal inflammation and immunity”
Invited Speaker, Tenth National Conference on Sjogren’s Syndrome, Cleveland, OH
“The eye in Sjogren’s syndrome- recent developments in understanding of disease pathogenesis and treatment strategies”
Annual Meeting of the Ocular Microbiology and Immunology Group, Orlando, FL
“ICAM-1 function is necessary for host sensitization to donor MHC antigens in corneal transplantation”
Annual Scientific Meeting of the Eye Bank Association of America, Orlando, FL
“Interleukin-1 receptor antagonist and prednisolone are comparable in their anti-inflammatory effect after corneal surgery”
Annual Meeting of the Castroviejo Cornea Society, Orlando, FL
“Cytokine and chemokine function in corneal transplantation immunology”
Invited Speaker, Ninth Iranian Congress of Ophthalmology, Tehran
“New developments in ocular immunology research”
Invited Speaker, Ninth Iranian Congress of Ophthalmology, Tehran
“Cellular and molecular mechanisms of ocular atopic disease”
Invited Speaker, Ninth Iranian Congress of Ophthalmology, Tehran
“High-risk corneal transplantation: old questions; new answers”
2000 Invited Speaker, Tufts University-New England Eye Center, Boston, MA
“Corneal manifestations of systemic diseases”
Invited Speaker, Allergan, Irvine, CA
“Role of inflammation and autoimmunity in Sjogren’s syndrome”
Invited Speaker, Biogen, Cambridge, MA
“Blockade of CD40L in corneal allosensitization”
Chairman and Session Moderator, “Pathology of meibomian glands”
First International Meeting on the Meibomian Gland: Meibom-2000
Boca Raton, FL
ARVO Annual Meeting, Ft. Lauderdale, FL
“Detection of donor-derived antigens and cells in draining lymph nodes after corneal transplantation”
Invited Speaker, IntraMed and Daichi Pharmaceutical, Phoenix, AZ
“Ocular disease in Sjogren’s syndrome and other immune-mediated surface pathologies”
Invited Speaker, 50th Anniversary Scientific Symposium of the Schepens Eye Research Institute, Boston, MA
“New insights into corneal inflammation and transplantation immunology”
Invited Speaker, XIV International Congress of Eye Research,
Santa Fe, NM
“Molecular mechanisms in the pathogenesis of ocular infection and inflammation”
Keynote Speaker, Third International Conference on the Lacrimal Gland, Tear Film, and Dry Eye Syndromes: Basic Science and Clinical Relevance, Maui
“Influence of cytokines, chemokines, and immunoactive agents in lacrimal gland and ocular surface immunity and inflammation”
Invited Speaker, American Academy of Ophthalmology, Dallas, TX
“Twenty five years of progress in corneal immunology- What have we learned?"
Invited Speaker, Department of Ophthalmology, Federal University of S. Paolo, Paulista School of Medicine, Sao Paulo, Brazil
“Indications, challenges, and outcomes in pediatric corneal transplantation”
Invited Speaker, Department of Ophthalmology, Federal University of S. Paolo, Paulista School of Medicine, Sao Paulo, Brazil
“The eye in Sjogren’s syndrome: Recent developments in understanding of disease pathogenesis and treatment strategies”
Invited Speaker, Department of Ophthalmology, Federal University of S. Paolo, Paulista School of Medicine, Sao Paulo, Brazil
“New developments in corneal transplantation immunology”
Invited Speaker, Department of Ophthalmology, Federal University of S. Paolo, Paulista School of Medicine, Sao Paulo, Brazil
“Outcomes analysis in sarcoid uveitis”
Invited Speaker, XIth Annual New England Ophthalmological Society Meeting of Ophthalmic Medical Personnel, Boston, MA
“Dry Eye Syndromes- Classification, diagnosis, and management”
2001 Invited Speaker, American Uveitis Society Winter Symposium, Vail, CO
“Current issues in topical therapy of ocular inflammation”
Invited Speaker, Vertex Pharmaceuticals, Cambridge, MA
“Role of IL-1 and other proinflammatory cytokines in ocular inflammation”
Invited Speaker, Oregon Health Sciences University, Portland, OR
“Novel facets of corneal antigen-presenting cell distribution and trafficking”
Invited Speaker, Second Symposium on Sjogren’s and Allied Disorders, Boston
“Current and emerging treatments for dry eye-associated ocular surface disease- promises and limitations”
Invited Speaker, Association for Research in Vision and Ophthalmology (ARVO) Minisymposium on Ocular Immuneregulation and Immunotherapy, Ft. Lauderdale, FL.
“Cytokine regulation of antigen-presenting cell function in the cornea and ocular surface”
Invited Speaker, NIH/National Eye Institute Dry Eye Initiative I,
Ft. Lauderdale, FL
“Tear film stability measurements in dry eye syndromes”
Invited Speaker, Sjogren’s Syndrome Foundation, Massachusetts Chapter.
“Sjogren’s Syndrome and the eye”
Invited Speaker, Rheumatology Grand Rounds, SUNY Stony Brook-Winthrop U. Department of Medicine
“Mechanisms and manifestations of ocular inflammation related to systemic disease”
Invited Speaker, Twenty Second Boston Biennial Cornea Conference, Boston, MA
“Heterogeneous group of resident and limbal bone marrow-derived CD45+ mediate the immune response to corneal antigens”
Invited Speaker, Institute of Ophthalmology and Department of Immunology, University College London
“Molecular regulation of corneal antigen presentation”
Invited Speaker, Moorfields Eye Hospital, London
“Modulation of sensitization to corneal antigens by suppressing antigen-presenting cell trafficking”
Invited Speaker, Symposium on Corneal Immunology, European Association for Vision and Eye Research, Alicante, Spain
“Skewing the corneal immune response: Molecular regulatory pathways of corneal and ocular surface APC trafficking”
Distinguished Speaker series, University of Alabama-Mobile, Department of Microbiology & Immunology
“Corneal antigen presentation is mediated by heterogeneous group of limbal and corneal bone marrow-derived cells”
Invited Speaker, 2001 ASORN Annual Meeting, New Orleans, LA
“Pathogenesis, classification, and treatment strategies in dry eye disorders”
Invited Speaker, Symposium on Sjogren’s Syndrome, Annual Meeting of the American College of Rheumatology, San Francisco, CA
“Immunopathogenesis of ocular sicca syndromes”
2002- Visiting Professor and Invited Speaker, Kyoto Prefec. University, Kyoto, Japan
“Induction of immunity to corneal antigens is mediated by both the direct and indirect routes of sensitization”
Course Co-Director, Harvard Medical International Master Workshop in Design and Conduct of Clinical Research, U. Tokyo, Tokyo, Japan
Invited Speaker, New England Ophthalmological Society, Boston
“Pathogenesis and treatment of dry eye syndromes”
Invited Speaker, Workshop in Ocular Immunology, Ettal, Germany
“Role of cytokines and chemokines in mediating adaptive immune responses in the cornea and ocular surface”
Invited Speaker, Vistakon/Johnson and Johnson, Jacksonville FL
“The classification, pathophysiology, and immunopathogenesis of dry eye syndromes”
Honored Alumnus Speaker, Peter C. Kronfeld Memorial Lecture, Illinois Eye & Ear Infirmary, Chicago IL
“Molecular mechanisms that regulate immune responses to corneal antigens”
Invited Speaker, International Symposium on Frontiers in Ocular Immunology, Inflammation, and Transplantation, London UK
“Molecular mechanisms of corneal antigen-presenting cell activation and recruitment”
Invited Speaker, Rheumatology Grand Rounds, SUNY Stony Brook-Winthrop U. Department of Medicine
“Immunopathogenesis of ocular inflammatory diseases”
Invited Speaker, First International Workshop on Corneal Immunology, Bermuda
“Phenotypic and functional characteristics of corneal APC in normal and inflamed eyes”
Invited Speaker, New England Ophthalmological Society, Boston
“Uveitis and ocular inflammation- persistent challenges in ophthalmology”
Invited Fry Lecturer, Biennial Cornea Conference, Wills Eye Hospital, Philadelphia PA
“Immunopathogenesis of corneal transplant rejection”
Invited Speaker, Biennial Cornea Conference, Wills Eye Hospital, Philadelphia PA
“Use of systemic immune suppression in inflammatory disorders of the cornea and sclera”
Invited Fry Lecturer, Biennial Cornea Conference, Wills Eye Hospital, Philadelphia PA
“To do or not to do: systemic immune suppression in high-risk corneal transplantation”
2003- Session Moderator, Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL.
“Immunology of corneal transplantation”
Invited Speaker, Colorado Rheumatism Society, Denver, CO
“Immunopathogenesis of autoimmune ophthalmic diseases”
Invited Speaker, New England Ophthalmological Society, Boston
“Dry Eye Syndromes: Diagnosis, classification, and novel therapeutic strategies”
Cogan Award Lecturer, Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL.
“Corneal antigen-presenting cells: Diversity, plasticity, and disguise”
Invited Speaker, Department of Immunology and Microbiology, Dartmouth Medical Center, Hanover NH
“Corneal antigen-presenting cells: Molecular mechanisms of recruitment and activation in an immune privileged site”
Conference Co-Chair and Speaker, First Harvard-wide Workshop on Cell Death and the Eye, Boston MA
“Examining the role of apoptosis in corneal decompensation after transplantation”
Dohlman Lecturer, Twenty-Third Boston Biennial Cornea Conference, Boston MA
“Corneal antigen-presenting cells: A Diverse Cast of Characters With Unknown intentions”
Invited Speaker, Workshop in Ocular Immunology, Ettal, Germany
“Function and activation of APCs in corneal transplantation”
Session Chair, Workshop in Ocular Immunology, Ettal, Germany
“Role of APCs in ocular pathology”
Invited Speaker, Thirteenth Iranian Congress of Ophthalmology, Tehran
“Ocular manifestations of systemic immune-mediated diseases”
Invited Speaker, Thirteenth Iranian Congress of Ophthalmology, Tehran
“Systemic immune modulation in inflammatory eye diseases. The state of the art, its promises, and limitations”
Invited Speaker, Thirteenth Iranian Congress of Ophthalmology, Tehran
“Immunobiology of corneal transplantation”
Invited Speaker, Thirteenth Iranian Congress of Ophthalmology, Tehran
“Immune modulation in high-risk corneal transplantation”
2004- Invited Alta Lecturer, University of California-San Francisco,
San Francisco, CA
“Immunopathogenesis of corneal transplant rejection”
Visiting Professor Lecture, Proctor Foundation, San Francisco
“Use of systemic immune modulators in corneal and scleral diseases”
Keynote Speaker, 28th Japan Cornea Conference & 20th Annual Meeting of The Keratoplasty Society of Japan , Yonago, Japan
“Molecular and cellular bases of Corneal Alloimmunity”
Visiting Professor and Invited Speaker, Kyoto Prefec. University, Kyoto, Japan
“Functional and phenotypic specificities of corneal antigen-presenting cells: what is known”
Major Teaching & Curriculum Offerings
1995- Founder, Ocular Immunology Service, Brigham & Women’s
Hospital. Developed new clinical and research program focusing on inflammatory and immune diseases of the eye, providing novel and expanded patient care and educational services, as well as clinical research venues. This service as also become an integral part in the training of fellows in the joint Partners Immunology and Allergy program.

1997-1998 American Academy of Ophthalmology
Instructor and course co-organizer: “Emerging concepts in the pathogenesis and treatment of corneal and ocular surface diseases”. Course provided overview of the fundamental molecular and cellular mechanisms of corneal and ocular surface diseases
1998- Harvard Intensive Review of Ophthalmology Course
Principal Instructor for Cornea and External Disease section of course.
1999 Organizer, Boston Symposium on Sjogren’s Syndrome and Allied Disorders. Organized the first Boston-wide symposium involving 18 faculty members from area universities and the NIH on the basic science and clinical aspects of autoimmune exocrinopathies.

1999- Harvard Intensive Review of Ophthalmology Course
Principal Instructor for Uveitis and Ocular Immunology section of course.

1999- Moderator, Annual Meeting of the Association for Research in Vision and Ophthalmology, Corneal Transplant Immunology section.
1999 Organizer, Mini-symposium on Corneal Transplant Immunology, Annual Scientific Meeting of the Castroviejo Cornea Society. Organized and moderated a mini-symposium dedicated to review of new developments in corneal transplant immunology research.
2001- Lancaster Course in Ophthalmology, sponsored by the Harvard Department of Ophthalmology
Instructor for Corneal and Ocular surface inflammation section of course.
2001- Conference Co-Chair, Harvard Biennial Cornea Research Conference.Report of Clinical Activities:
1. Clinical Practice: Cornea/External Disease, and Ocular Immunology.
Full-time hospital-based academic faculty at Mass. Eye and Ear Infirmary. In addition, I am involved in clinical research in the areas of ocular surface and inflammatory diseases.
2. Patient load: I devote 20-25% of my time to clinical activities comprised of medical and surgical subspecialty care of patients with corneal and inflammatory ocular diseases. All patients are evaluated and managed with trainees.
3. Contributions: Development of a new multidisciplinary Ocular Immunology service at BWH (1995-2002) focusing on management of patients with ocular immunoinflammatory conditions. This streamlined the care of these patients, and provided new educational opportunities for ophthalmology and immunology trainees at the Longwood Medical Area. Upon termination of BWH Ophthalmology service in 2002, my related clinical and academic activities were transferred entirely to the Mass. Eye and Ear Infirmary.
Bibliography:
Original Articles
1. Young EM, Olkowski ST, Dana MR, Mallette RA, Stark WJ. Pretreatment of donor corneal endothelium with ultraviolet-B irradiation. Transplantation Proc 1989; 21:3145-6.
2. Dana MR, Tielsch JM, Enger C, Joyce E, Santoli JM, Taylor HR. Visual impairment in a rural Appalachian community. Prevalence and causes. JAMA 1990; 264: 2400-5.
3. Dana MR, Olkowski ST, Ahmadian H, Stark WJ, Young EM. Low-dose ultraviolet-B irradiation of donor corneal endothelium and graft survival. Invest Ophthalmol Vis Sci. 1990; 31: 2261-8.
4. Dana MR, Putz JL, Viana MAG, Sugar J, McMahon TT. Contact lens failure in keratoconus management. Ophthalmology 1992; 99: 1187-92.
5. Dana MR, Werner MS, Viana MAG, Shapiro MJ. Spontaneous and traumatic vitreous hemorrhage. Ophthalmology 1993; 100: 1377-83.
6. Dana MR, Mori MT, Chandler JW, McMahon TT. Artificial orbit for experimental anterior segment surgery. Arch Ophthalmol 1994; 112: 125-8.
7. Dana MR, Hochman M, Viana MAG, Hill C, Sugar J. Ocular manifestations of leprosy in the United States. Arch Ophthalmol 1994; 112: 626-9.
8. Dana MR, Mori MT, Viana MAG, McMahon TT, Chandler JW. Dynamic shifts in corneal topography after radial and transverse keratotomy. Ophthalmology 1994; 101: 1818-26.
9. Werner MS, Dana MR, Viana MAG, Shapiro MJ. Predictors of occult scleral rupture. Ophthalmology 1994; 101: 1941-44.
10. Dana MR, Goren MB, Gomes JAP, Laibson PR, Rapuano CJ, Cohen EJ. Suture erosion after penetrating keratoplasty. Cornea 1995; 14: 243-8.
11. Gomes JAP, Dana MR, Dua HS, Goren MB, Laibson PR, Cohen EJ. Donor rim culture in penetrating keratoplasty. Cornea 1995; 14: 457-62.
12. Dana MR, Moyes AL, Gomes JAP, Rosheim KM, Schaumberg DA, Sugar A, Holland EJ, Laibson PR, Sugar J. The indications for and outcome in pediatric keratoplasty: a multicenter study. Ophthalmology 1995; 102: 1129-1138.
13. Dana MR, Schaumberg DA, Kowal VA, Goren MB, Rapuano CJ, Cohen EJ, Laibson PR. Predictors of corneal neovascularization after penetrating keratoplasty. Cornea 1995; 14: 604-9.
14. Dana MR, Schaumberg DA, Moyes AL, Gomes JAP, Holland EJ, Laibson PR, Sugar A, Sugar J. Outcome of penetrating keratoplasty for ocular trauma in children. Arch Ophthalmol 1995; 113: 1503-7.
15. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996; 103: 1846-53.
16. Dana MR, Streilein JW. Corneal neovascularization and ocular immune privilege. Invest Ophthalmol Vis Sci. 1996; 37: 2485-94.
17. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology 1997; 104: 236-44.
18. Goren MB, Dana MR, Rapuano CJ, Gomes JAP, Cohen EJ, Laibson PR. Corneal topographic effects of selective suture removal for post-keratoplasty astigmatism. Ophthalmic Surgery and Lasers 1997; 28: 208-14.
19. Dana MR, Yamada J, Streilein JW. Topical interleukin-1 receptor antagonist promotes corneal transplant survival. Transplantation 1997; 63: 1501-7.
20. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness. Five paths to herpes stromal keratitis. Immunology Today 1997: 18: 443-9.
21. Dana MR, Chatzistefanou K, Schaumberg DA, Foster CS. Posterior capsular opacification in uveitis patients. Ophthalmology 1997; 104: 1387-94.
22. Dana MR, Schaumberg DA, Moyes AL, for the Multicenter Pediatric Keratoplasty Study Group. Keratoplasty for Peters anomaly and other mesenchymal dysgeneses. A multicenter study. Ophthalmology 1997; 104: 1580-6.
23. Schaumberg DA, Snow KK, Dana MR. The epidemic of Acanthamoeba keratitis. Where do we stand? Cornea 1998; 17: 3-10.
24. Dana MR, Dai R, Zhu S, Yamada J, Streilein JW. Interleukin-1 receptor antagonist suppresses corneal Langerhans cell activity and promotes ocular immune privilege, Invest Ophthalmol Vis Sci. 1998; 39: 70-7.
25. Sullivan DA, Rocha EM, Ullman MD, Krenzer KL, Gao J, Toda I, Dana MR, Wickman LA. Androgen regulation of the meibomian gland. Adv Exp Med Biol 1998; 438: 327-31.
26. Schaumberg DA, Dana MR, Christen WG, Glynn RJ. A systematic overview of posterior capsular opacification. Ophthalmology 1998; 105: 1213-21.
27. Dana MR, Zhu S, Yamada J. Topical modulation of interleukin-1 activity in corneal inflammatory neovascularization, Cornea: 1998; 17: 403-9.
28. Yamada J, Dana MR, Zhu S, Alard P, Streilein JW. Suppression of allosensitization in corneal transplantation by modulation of IL-1 activity, Arch Ophthalmol 1998: 116: 1351-57.
29. Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplantation Pr 1999; 31: 1472-5.
30. Schaumberg DA, Ridker P, Glynn R, Christen W, Dana MR, Hennekens C. C-Reactive Protein levels predict future risk of age-related cataract, Ann Epidemiology 1999; 9: 166-71.
31. Goslings WRO, Yamada J, Dana MR, Streilein JW, Prodeus AP, Carroll MC, Jager MJ. Corneal transplant survival in antibody- and complement-deficient hosts. Invest Ophthalmol Vis Sci. 1999; 40: 250-3.
32. Sullivan DA, Krenzer KL, Sullivan BD, Bazzinotti D, Toda I, Wickham LA, Dana MR. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci. 1999; 40: 1261-5.
33. Schaumberg DA, Moyes AL, Dana MR for the Multicenter Pediatric Keratoplasty Study Group. Keratoplasty for congenital hereditary endothelial dystrophy (CHED). Am J Ophthalmol 1999; 127: 373-8.
34. Dekaris I, Zhu S, Dana MR. Tumor necrosis factor-alpha regulates corneal Langerhans cell migration. J Immunol 1999; 162: 4235-9.
35. Zhu S, Dana MR. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci. 1999; 40: 1427-34.
36. Zhu SN, Dekaris I, Duncker G, Dana MR. Early expression of proinflammatory cytokines interleukin-1 and tumor necrosis factor-alpha after corneal transplantation. J Interfer Cytokine Res 1999; 19: 661-9.
37. Sullivan DA, Wickham LA, Rocha EM, Krenzer KL, Sullivan BD, Steagall R, Cermak J, Dana MR et al. Androgens and dry eye in Sjogren’s syndrome. Ann NY Acad Sci 1999; 876: 312-24.
38. Yamagami S, Miyazaki D, Ono SJ, Dana MR. Differential chemokine gene expression in corneal transplant rejection. Invest Ophthalmol Vis Sci. 1999; 40: 2892-7.
39. Dekaris I, Yamada J, Streilein JW, Dana MR. Effect of topical interleukin-1 receptor antagonist (IL-1ra) on corneal allograft survival in presensitized hosts. Curr Eye Res 1999; 19: 456-9.
40. Yamada J, Streilein JW, Dana MR. Role of tumor necrosis factor receptors TNFR-I (p55) and TNFR-II (p75) in corneal transplantation. Transplantation 1999: 68: 944-9.
41. Keane-Myers AM, Miyazaki D, Liu G, Dekaris I, Ono SJ, Dana MR. Treatment with IL-1ra prevents allergic eye disease. Invest Ophthalmol Vis Sci. 1999; 40: 3041-6.
42. Zhu SN, Yamada J, Streilein JW, Dana MR. ICAM-1 deficiency suppresses host allosensitization and rejection of MHC-disparate corneal transplants. Transplantation 2000: 69: 1008-13.
43. Dana MR, Qian Y, Hamrah P. Twenty-five year panorama of corneal immunology: Emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 2000; 19: 625-43.
44. Qian Y, Dekaris I, Yamagami S, Dana MR. Topical soluble tumor necrosis factor alpha receptor I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol 2000; 118: 1666-71.
45. Yamada J, Zhu SN, Streilein JW, Dana MR. Interleukin-1 Receptor Antagonist therapy and induction of Anterior Chamber Associated Immune Deviation (ACAID)-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000; 41: 4203-8.
46. Sullivan BD, Evans JE, Krenzer KL, Dana MR, Sullivan DA. Impact of anti-androgen treatment on the fatty acid profile of neutral lipids in human meibomian gland secretions. J Cl Endocr Metabolism 2000; 85: 4866-73.
47. Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, Sullivan DA. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Cl Endocr Metabolism 2000; 85: 4874-82.
48. Graham M, Azar N, Dana MR. Visual rehabilitation in children with congenital hereditary endothelial dystrophy. Int Ophthalmol Cl 2001; 41: 9-18.
49. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after silicone punctal occlusion in dry eye syndromes. Am J Ophthalmol 2001; 131: 30-36.
50. Khadem J, Dana MR. Photodynamic biologic tissue glue in perforating rabbit corneal wounds. J Cl Laser Med Surg 2001; 18: 125-9.
51. Qian Y, Boisgerault F, Benichou G, Dana MR. Blockade of CD40-CD40L costimulatory pathway promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci. 2001; 42: 987-94.
52. Qian Y, Dana MR. Molecular mechanisms of immunity in corneal allotransplantation and xenotransplantation. Expert Rev Mol Med. 2001; 3:1-21.
53. Boisgerault F, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G. Role of CD4+ and CD8+ T cells in allorecognition. Lessons from corneal transplantation. J Immunol 2001; 167: 1891-1899.
54. Yamagami S, Dana MR. The critical role of draining lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001; 42:1293-1298.
55. Dana MR, Sullivan DA, Parke AL. Toward optimal health: Experts discuss dry eye syndrome. J Womens Health Gend Based Med 2001; 10:725-729.
56. Liu Y*, Dana MR*, Tewari V, Taylor AW. Immune response to intragraft antigen in draining lymph nodes after corneal transplantation is mediated by IL-12. J Interfer Cytokine Res 2001; 21: 813-819.
57. Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology 2001; 108: 1682-1687.
58. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Hormone replacement therapy and the prevalence of dry eye syndrome in women. JAMA 2001; 286:2114-2119.
59. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cells. Invest Ophthalmol Vis Sci. 2002; 43: 639-646.
60. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, Suzuki T, Schaumberg DA, Sullivan RM, Dana MR. Androgen deficiency, meibomain gland dysfunction, and evaporative dry eye. Ann NY Acad Sci 2002: 966:211-222.
61. Maw R, Pasquale LR, Pineda R, Dana MR. Traumatic ruptured globe injuries in children. Int Ophthalmol Cl 2002: 42:157-165.
62. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of goblet cell mucin MUC5AC in tears of Sjogren’s syndrome patients. Invest Ophthalmol Vis Sci. 2002; 43: 1004-1011.
63. Sakai R, Kinouchi T, Kawamoto S, Dana MR, Hamamoto T, Tsuru T, K Okubo, Yamagami S. Construction of Human Corneal Endothelial cDNA Library and Identification of Novel Active Genes. Invest Ophthalmol Vis Sci. 2002; 43: 1749-1756.
64. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 2002; 21:405-9.
65. Liu Y*, Hamrah P*, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor MHC class II-positive dendritic cells derived from MHC class II-negative grafts (*co-first authors). J Exp Medicine 2002; 195: 259-268.
66. Cermak JM, Papas AS, Sullivan RM, Dana MR, Sullivan DA. Nutrient intake in women in primary and secondary Sjogren’s syndrome. Eur J Cl Nutr 2003; 57:328-334.
67. Suzuki T, Schaumberg DA, Sullivan BD, Liu M, Richards SM, Sullivan RM, Dana MR, Sullivan DA. Do estrogen and progesterone play a role in the dry eye of Sjogren’s syndrome? Ann NY Acad Sci 2002; 966:223-225.
68. Qian Y, Dana MR. Effect of locally administered anti-CD154 (CD40L) monoclonal antibody on survival of allogeneic corneal transplants. Cornea 2002; 21:592-597.
69. Zierhut M, Dana MR, Stern ME, Sullivan DA. Immunology of the lacrimal gland and ocular tear film. Tr Immunol 2002; 23:333-335.
70. Yi DA, Dana MR. Corneal edema after cataract surgery: incidence and etiology. Sem Ophthalmol 2002; 17:110-4.
71. Ohta K, Yamagami S, Wiggert B, Dana MR, Streilein JW. Chemokine gene expression in iris-ciliary body during experimental autoimmune uveoretinitis. Curr Eye Res 2002; 24:451-457.
72. Sullivan BD, Evans JE, Cermak JM, Krenzer KL, Dana MR, Sullivan DA. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Arch Ophthalmol 2002; 120:1689-1699.
73. Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res 2003; 76:161-167.
74. Qian Y, Hamrah P, Boisgerault F, Yamagami S, Vora S, Benichou B, Dana MR. Mechanisms of Immunotherapeutic Intervention by Anti-CD154 (CD40L) Antibody in High-Risk Corneal Transplantation. J Interfer Cytokine Res 2002; 22:1217-1225.
75. Hamrah P, Liu Y, Dana MR. The corneal stroma is endowed with significant numbers of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003; 44:581-589.
76. Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface? Cornea 2003; 22:516-521.
77. Yamagami S, Hamrah P, Zhang Q, Liu Y, Huq S, Dana MR. Early ocular chemokine gene expression after high-risk corneal transplantation. Submitted, J Interfer Cyt Res.
78. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003: 136:318-326.
79. Hamrah P, Huq S, Liu Y, Zhang Q, Dana MR. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leuk Bio 2003; 4:172-176.
80. Mendes F, Schaumberg DA, Navon S, Steinert R, Sugar J, Holland EJ, Dana MR. Assessment of Visual Function after Corneal Transplantation – The Quality of Life and Psychometric Assessment after Corneal Transplantation (Q-PACT) Study. Am J Ophthalmol 2003: 135:785-793.
81. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: Evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003; 22:273-281.
82. Hamrah P, Chen L, Zhang Q, Dana MR. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-c on corneal dendritic cells. Am J Path 2003: 163:57-68.
83. Hamrah P, Liu Y, Qiang Z, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol 2003; 121:1132-1140.
84. Dana MR. Corneal antigen-presenting cells: Diversity, plasticity, and disguise. Invest Ophthalmol Vis Sci 2004; 45:722-727.
85. Sullivan DA, Belanger, Cermak JM, Berube R, Papas AS, Sullivan RM, Yamagami H, Dana MR, Labrie F. Are women with Sjogren’s syndrome androgen-deficient? J Rheum 2003: 30:2413-19.
86. Gardiner MF, Pineda R, Dana MR. Laser cataract surgery: past, present, and evolving technologies. Int Ophthalmol Clin. 2004; 44:113-21
87. Barabino S, Dana MR. Animal models of dry eye: a critical assessment of opportunities and limitations. Invest Ophthalmol Vis Sci 2004: in press.
88. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW. Roles of thrombospondin 1 and 2 in regulating corneal and iris neovasculization. Invest Ophthalmol Vis Sci 2004: in press. .
89. Qian Y, Leong F, Kazlauskas A, Dana R. Ex Vivo Adenovirus-Mediated Gene Transfer to Corneal Graft Endothelial Cells in Mice. Investigative Ophthalmology and Vis Sci 2004: in press.
90. Cursiefen C, Chen L, Borges L, Jackson D, Cao J, Radziejewski C, D’Amore P, Dana MR, Weigand SJ, Streilein JW. VEGF-A stimulates lymph- and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004: in press.
91. Hamrah P, Chen L, Zhang Q, Joyce NC, Dana MR. Novel identification of vascular endothelial growth factor receptor-3 (VEGFR-3) expression by monocytic bone marrow-derived cells in the conjunctiva. Submitted.
92. Yi D, Cibas ES, Arrigg PG, Dana MR. Unilateral hypopyon as manifestation of adult relapsing acute lymphoblastic leukemia. Submitted.
93. Dekaris I, Dana MR. Effect of soluble tumor necrosis factor-alpha receptor I (sTNFR-I) on Langerhans cell recruitment. Submitted

94. Hamrah P*, Zhu SN*, Yamada J, Dana MR. Interleukin-1 receptor antagonist and corticosteroids have comparable efficacy in promoting corneal transplant survival (*co-first authors). Submitted.
Proceedings & Transactions
95. Yamada J, Dana MR, Zhu S, Streilein JW. Promotion of allogeneic corneal transplant survival by interleukin-1 receptor antagonist is mediated by suppression of allosensitization. Fifth Basic Sciences Symposium of the Transplantation Society 1997.
96. Dana MR, Yamagami S, Hamrah P, Dekaris I, Zhu S. Inflammatory cytokines and cytokine receptors in corneal inflammation and immunity. Proceedings of the International Society for Eye Research, Volume XIV, 2000: S184.
97. Dana MR. Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye. Adv Exp Med Biol 2002; 506: 729-738.
98. Hamrah P, Zhang Q, Dana MR. Expression of vascular endothelial growth factor receptor-3 (vegfr-3) in the conjunctiva: A potential link between lymphangiogenesis and leukocyte trafficking on the ocular surface. Adv Exp Med Biol 2002; 506: 851-860.
99. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol 2002; 506: 989-998.
100. Sullivan RM, Cermak JM, Papas AS, Dana MR, Sullivan DA. Economic and quality of life impact of dry eye symptoms in women with Sjögren’s Syndrome. Adv Exp Med Biol 2002; 506: 1183-1188.
101. Sullivan BD, Cermak JM, Sullivan RM, Papas AS, Evans JE, Dana MR, Sullivan DA. Correlations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren’s Syndrome. Adv Exp Med Biol 2002; 506: 441-447.
102. Sullivan BD, Evans JE, Dana MR, Sullivan DA. Impact of androgen deficiency on the lipid profiles in human meibomian gland secretions. Adv Exp Med Biol 2002; 506: 449-458.
103. Sullivan DA, Yamagami H, Liu M, Steagall RJ, Schirra F, Suzuki T, Krenzer KL, Cermak JM, Sullivan RM, Richards S, Dana MR, Sullivan BD. Sex steroids, the meibomian gland and evaporative dry eye. Adv Exp Med Biol 2002; 506: 389-399.
104. Sullivan DA, Schaumberg DA, Suzuki T, Schirra F, Liu M, Richards S, Sullivan RM, Dana MR, Sullivan BD. Sex steroids, meibomian gland dysfunction and evaporative dry eye in Sjogren’s syndrome. Lupus 2002; 11:667.
Reviews & Chapters
105. Schaumberg DA, Dana MR. The epidemiology of world blindness. Prac Opt 1996: 7: 192-6.
106. Dana MR. Cataract surgery in the uveitis patient. Rev Ophthalmology 1997; 4: 190-4.
107. Davis E, Dana MR. Pregnancy and the Eye. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4767-83; Philadelphia: WB Saunders Co., 1999.
108. Dana MR, Reddy CV, Foster CS. Adult Rheumatoid Arthritis. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4555-62; Philadelphia: WB Saunders Co., 1999.
109. Dana MR, Reddy CV, Foster CS. Scleroderma. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4589-95; Philadelphia: WB Saunders Co., 1999.
110. Kim R, Dana MR. Graft-Versus-Host Disease. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4994-01; Philadelphia: WB Saunders Co., 1999.
111. Dana MR. Uveitis in juvenile rheumatoid arthritis (JRA). In: Fraunfelder FT, Roy H. Current Ocular Therapy. Fifth Edition: 176-178; Philadelphia: WB Saunders Co., 1999.
112. Dana MR. Uveitis in leptospirosis. In: Foster CS (Ed.) Textbook of Uveitis. Philadelphia: WB Saunders Co., 2002: 273-77.
113. Dana MR. Ocular immunology. Chapter IX, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
114. Dana MR. Clinical approaches to immune-related disorders of the external eye. Chapter X, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
115. Dana MR. Wound healing of the conjunctiva, cornea, and sclera. Chapter XIX, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
116. Dana MR. Toxic and traumatic injuries of the anterior segment. Chapter XX, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
117. Dana MR. Introduction to surgery of the ocular surface. Chapter XXI, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
118. Dana MR. Surgical procedures of the ocular surface. Chapter XXII, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
119. Sullivan DA, Schaumberg DA, Schirra F, Suzuki T, Liu M, Richards SM, Sullivan RM, Dana MR, Sullivan BD. Hormone therapy for dry eye- Topical androgen administration may be an effective therapy for the treatment of dry eye syndromes. Rev Ophthalmol 2002: in press.
120. Dana MR. Transplantation Immunology. Chapter XXII, Section 8, Basic and Clinical Science Course, American Academy of Ophthalmology, San Francisco, 2002.
121. Gulati A, Dana MR. Eye complications after hematopoietic stem cell transplantation. In: Atkinson K, Ed. Clinical Bone Marrow and Blood Stem Cell Transplantation. Third Ed. Cambridge U Press, 2004: 1550-1561.
122. Sullivan DA, Schaumberg DA, Schirra F, Suzuki T, Richards SM, Liu M, Sullivan RM, Dana MR, Sullivan BD. Sex, sex stroids, and dry eye syndromes. In: Zierhut M, Ed. Immunology of the Lacrimal Gland and Ocular Tear Film. Swets & Zeitlinger, 2003.
123. Dana MR, Hamrah P. Corneal antigen-presenting cells: function and indentity. In: Zierhut M, Ed. Immunology of the Lacrimal Gland and Ocular Tear Film. Swets & Zeitlinger, 2004.
124. Dana MR. Keratoconjunctivitis sicca. In: Foster CS, Azar DT, Dohlman CH, Eds. Smolin & Thoft’s The Cornea. Fourth Ed. Lippincott Williams & Wilkins, 2003.
125. Hamrah P, Huq SO, Gulati A, Dana MR. Mechanisms of the ocular surface immune response. In: Pflugfelder S, Beuerman R, Stern M, Eds. Dry Eye and Ocular Surface Disorders. Chapter 6, pp: 111-142, Marcel Dekker, 2004.
126. Cursiefen C, Seitz B, Dana MR, Streilein JW. Angiogenese und Lymphangiogenese. Der Ophthalmologe 2003: 100: 292-299.

Books And Monographs
1. Dana MR, Jakobiec FA, section eds. The Eye and Systemic Disease. In: Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. 2nd Ed. Philadelphia: WB Saunders Co., 1999.
Clinical Communications
1. Dana MR, Rosheim K. Case-control study of retinal vein occlusion [Letter]. Ophthalmology 1992; 99: 1754-5.
2. Dana MR, Wilensky JT. Immune-related disease and normal-tension glaucoma [Letter]. Arch Ophthalmol 1993; 111: 22-3.
3. McMahon TT, Dana MR, Sugar J. Keratoconus contact lens failure [Letter]. Ophthalmology 1993; 100: 147-8.
4. Dana MR, Werner MS. "Sterile" endophthalmitis after sutureless cataract extraction [Letter]. Ophthalmology 1993; 100: 441-2.
5. Schaumberg DA, Dana MR. Is smoking a risk factor for non-arteritic AION? [Letter] Ophthalmology 1994; 101: 1765.
6. Schaumberg DA, Dana MR. Visual prognosticators in Behçet uveitis [Letter]. Ophthalmology 1995; 102: 1739.
7. Dana MR. Outcomes in pediatric keratoplasty [Letter]. Ophthalmology 1996; 103:202-3.
8. Dana MR. Dry Eye Syndrome. HealthNews (patient educational publication of the New England Journal Of Medicine), 1998; 4: 3.
9. Schaumberg DA, Dana MR, Foster CS. Posterior capsule opacification after cataract surgery. Ophthalmology 1998; 105: 943-4.
10. Dana MR. Phacoemulsification in Behcet’s syndrome [Commentary]. Ocular Surgery News 2001; 12: 52.
Educational Materials & Course Syllabi
1. Dana MR. New curriculum for Cornea/External Disease section of Harvard Intensive Review of Ophthalmology Course, 1998: Developed 60+ page handout for course covering corneal anatomy, dystrophies, degenerations, metabolic disorders, ocular atopy, corneal and ocular surface inflammatory conditions, sicca syndromes, scleritis and corneal manifestations of connective tissue diseases, and corneal and conjunctival surgery.
2. Dana MR. Curriculum for Ocular Immunology section of Harvard Intensive Review of Ophthalmology Course, 1999: Developed 40+ handout for course covering fundamentals of immunology, and clinical aspects of ocular immunology, uveitis and infectious and autoimmune uveo-retinal syndromes.
Nonprint Materials
1. Dana MR. Ocular disease in rheumatoid arthritis. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1997.
2. Tolentino M, Dana MR. Retinal vasculitis associated with systemic disorders and infections. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1998.
3. Garrana R, Dana MR. Episcleritis and scleritis. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1998.
4. Tolentino M, Dana MR. Retinal vasculitis associated with primary ocular disorders. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1998
5. Dana MR. Uveitis in juvenile rheumatoid arthritis. E-Medicine Textbook of Ophthalmology, 1999.
6. Dana MR. Anterior uveitis: The Uveitis Disease Center, YourDoctor.com, 2000.
7. Dana MR. Uveitis and ocular inflammation: Vcure.com, 2000.
8. Dana MR. Cataract: Vcure.com, 2000.
9. Dana MR. Dry eyes and Sjogren’s syndrome: Vcure.com, 2000.
10. Dana MR. Ocular allergy: Vcure.com, 2000.
11. Dana MR. Ocular herpetic infections: Vcure.com, 2000.
12. Dana MR. Systemic diseases and the eye: Vcure.com, 2000.
13. Dana MR. Ocular trauma: Vcure.com, 2000.
14. Dana MR. Corneal transplantation: Vcure.com, 2001.
15. Dana MR. Corneal dystrophies and genetic anomalies: Vcure. Com, 2001.
16. Maw R, Dana MR. Ocular atopic diseases. In: Schur PH, ed. UpToDate in Allergy and Immunology. Wellesley: UpToDate Inc., 1998

Patents
1. Dana MR. Local use of IL-1ra for prophylaxis and treatment of corneal transplant rejection and other immune and inflammatory disorders of the eye. Patent PCT/US97/21393. Filed November 19, 1997
2. Dana MR. Use of soluble tumor necrosis factor receptor I (sTNFRI) to promote survival of corneal transplants and treat inflammatory disorders of the eye. PCT/US99/26262. Filed November 6, 1998.
3. Dana MR, Vaishnaw A, Burkly L, Adelman B. Use of CD40:CD154 binding interrupter to treat immunological complications of the eye. PCT/US00/28945. Filed October 21, 1999.
4. Dana MR, Kazlauskas A. Promotion of corneal graft survival by anti-apoptotic gene therapy. US Patent Application 60/304,975 filed July 2001.
5. Dana R, Chen L, Streilein JW. Method of suppressing immunity by inhibiting trafficking of antigen-presenting cells. US Patent Application 60/447,570 filed February 2003
6. Dana R, Schaumberg DA. Topical use of a combination of fatty acids for treatment of ocular surface and adnexal inflammation. US Patent Application 60/475,194 filed June 2003.
Abstracts
1. Dana MR, Tielsch JM, Enger C, Santoli JM, Taylor HR. Visual impairment in rural Appalachia. Invest Ophthalmol Vis Sci. 1989; 30(Suppl): 495.
2. Dana MR, Olkowski ST, Ahmadian H, Stark WJ, Young EM. Ultraviolet-B irradiation of donor corneal endothelium and graft survival. Invest Ophthalmol Vis Sci. 1990; 31(Suppl): 271.
3. Dana MR, Putz JL, Viana MAG, Sugar J. Contact lens failure in keratoconus management. Invest Ophthalmol Vis Sci. 1991; 32(Suppl): 1114.
4. Dana MR, Werner MS, Viana MAG, Shapiro MJ. The causes and prognosis of vitreous hemorrhage in an urban population. Invest Ophthalmol Vis Sci. 1992; 33(Suppl): 860.
5. Werner MS, Dana MR, Viana MAG, Shapiro MJ. Preoperative predictors of ruptured globes. Invest Ophthalmol Vis Sci. 1992; 33(Suppl): 1312.
6. Dana MR, Hochman M, Viana MAG, Hill C, Sugar J. Ocular manifestations of Hansen's disease in a non-institutionalized community in the US. Invest Ophthalmol Vis Sci. 1993; 34(Suppl): 1296.
7. Gomes JAP, Dana MR, Dua HS, Goren MB, Laibson PR, Cohen EJ. Donor rim culture in penetrating keratoplasty. Cornea 1994; 13: 101.
8. Dana MR, Goren MB, Gomes JAP, Laibson PR, Rapuano CJ, Cohen EJ. Risk factors for suture erosion after penetrating keratoplasty. Invest Ophthalmol Vis Sci. 1994; 35(Suppl): 1476.
9. Goren MB, Dana MR, Gomes JAP, Dua HS, Cohen EJ, Rapuano CJ, Laibson PR. Stability of corneal topography following suture removal for post-keratoplasty astigmatism. Invest Ophthalmol Vis Sci. 1994; 35(Suppl): 1476.
10. Dana MR, Moyes AL, Gomes JAP, Rosheim KM, Holland EJ, Sugar J, Laibson PR, Sugar A. Indications and outcome of pediatric keratoplasty. Ophthalmology 1994; 101(Suppl.): 65.
11. Dana MR, Schaumberg DA, Moyes AL, Gomes JAP, Laibson PR, Holland EJ, Sugar A, Sugar J. Outcome of penetrating keratoplasty for ocular trauma in children: a multicenter experience. Invest Ophthalmol Vis Sci. 1995; 36(Suppl.): S652.
12. Rapuano CJ, Dana MR, Gomes JAP, Laibson PR. Astigmatic effect of graft alignment in penetrating keratoplasty. Invest Ophthalmol Vis Sci. 1995; 36 (Suppl.): S653.
13. Dana MR, Goren MB, Gomes JAP, Laibson PR, Rapuano CJ, Cohen EJ. Suture erosion after penetrating keratoplasty. Ophthalmology Digest 1995.
14. Dana MR, Merayo-Lloves J, Foster CS. Outcomes Analysis in ocular sarcoidosis. Ophthalmology 1995; 102 (Suppl.): 138.
15. Dana MR, Foster CS. Outcomes Analysis in JRA-associated Uveitis. Ocular Immunol Inflamm 1996; 4: 130.
16. Dana MR, Foster CS. Outcomes Analysis in JRA-associated uveitis. Cornea 1996; 15.
17. Dana MR, Sano Y, Streilein JW. The role of lymphangiogenesis and infiltrating Langerhans cells in the loss of immune privilege in the cornea. Invest Ophthalmol Vis Sci. 1996; 37 (Suppl.): S1136.
18. Goins KM, Khadem J, Dana MR, Majmudar P, Ernest JT. The effect of photodynamic biologic tissue adhesive on corneal wound healing after radial keratotomy. Invest Ophthalmol Vis Sci. 1996; 37 (Suppl.): S321.
19. Dana MR, Chatzistefanou K, Schaumberg DA, Foster CS. Posterior capsule opacification after cataract surgery in uveitis patients. Ophthalmology 1996; 103 (Suppl.): 117.
20. Dana MR, Moyes A, Schaumberg DA, Gomes JAP, and The Multicenter Pediatric Keratoplasty Study Group. Corneal transplantation in Peters’ anomaly and anterior chamber cleavage syndromes. Ophthalmology 1996; 103 (Suppl.): 133-4.
21. Streilein JW, Sano Y, Dana MR, Ksander B. Langerhans cells play a central role in promoting corneal allograft rejection. Proceedings of the Fourth International Symposium on Ocular Inflammation, 1996.
22. Sullivan DA, Rocha EM, Ullman MD, Krenzer KL, Gao J, Toda I, Dana MR, Wickman LA. Androgen regulation of the meibomian gland. Proceedings of the Second International Conference on the Lacrimal Gland, Tear Film, and Dry Eye Syndromes 1996.
23. Dana MR, Dai R, Yamada J, Streilein JW. Topical interleukin-1 receptor antagonist (IL-1ra) suppresses Langerhans cell activity and promotes immune privilege. [Abstract]. Invest Ophthalmol Vis Sci. 1997; 38 (Suppl.): S705.
24. Sullivan DA, Wickham LA, Ullman MD, Toda I, Dana MR, Bazzinotti D, Krenzer KL. Androgen control of the meibomian gland. Invest Ophthalmol Vis Sci. 1997; 38 (Suppl.): S444.
25. Zhu SN, Nolle B, Dana MR, Duncker G. In vitro evidence indicating detrimental effects of high-dose tissue plasminogen activator on corneal endothelium. Invest Ophthalmol Vis Sci. 1997; 38 (Suppl.): S1097.
26. Yamada J, Dana MR, Zhu S, Streilein JW. Promotion of allogeneic corneal transplant survival by interleukin-1 receptor antagonist is mediated by suppression of allosensitization. Fifth Basic Sciences Symposium of the Transplantation Society, 1997.
27. Dana MR, Balaram M. Ocular surface disease after allogeneic bone marrow transplantation. Ophthalmology 1997; 104 (Suppl.): 192.
28. Dana MR, Yamada J. Role of the TNF-a receptor 1 (TNF-R1) and receptor II (TNF-RII) activity in corneal allotransplantation and post keratoplasty neovascularization. Invest Ophthalmol Vis Sci. 1998; 39 (Suppl): S456.
29. Tei M, Spurr-Michaud SJ, Tisdale AS, Dana MR, Gipson IK. Quantitation of MUC5AC mRNA and protein in human conjunctiva. Invest. Ophthalmol Vis Sci. 1998; 39 (Suppl): S665.
30. Zhu S-N, Yamada J, Dana MR. Corneal inflammation and transplant survival in mice deficient in intercellular adhesion molecule-1 (ICAM-1). Invest. Ophthalmol Vis Sci. 1998; 39 (Suppl): S1067.
31. Sullivan DA, Sullivan BD, Toda I, Wickham LA, Dana MR. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest. Ophthalmol Vis Sci. 1998; 39 (Suppl): S1099.
32. Dekaris I, Yamada J, Zhu S-N, Dana MR. The TNF-a receptor mediates centripetal Langerhans cell migration after corneal stimulation. Invest. Ophthalmol Vis Sci. 1998; 39 (Suppl): S1120.
33. Dana MR, Dekaris I, Yamada J, Zhu SN. Role of tumor necrosis factor-alpha receptor activity in corneal transplantation. Ocular Imm Inflammation 1998; 6 (Suppl): S39.
34. Goslings WRO, Yamada J, Dana MR, Streilein JW, Prodeus AP, Carroll MC, Jager MJ. Corneal transplant survival in antibody- and complement-deficient mice. Ocular Imm Inflammation 1998; 6 (Suppl): S48.
35. Sullivan DA, Wickham LA, Rocha EM, Krenzer KL, Sullivan BD, Dana MR, Steagall R, Ullman MD, Bazzinotti D, Silveira LA, Cermak J, Toda I. Androgens and dry eye syndrome. Ann NY Acad Sci 1999; in press.
36. Balaram, M, Dana, MR. Outcomes following silicone punctal plugs in dry eyes. Invest. Opthalmol. Vis. Sci. 1999; 40 (Suppl): S541.
37. Yamada J, Zhu SN, Streilein JW, Dana MR. ACAID promoting properties of topical IL-1RA therapy. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S248.
38. Liu Y, Taylor AW, Dana MR. Immune Response to antigens of orthotopic corneal grafts. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S250.
39. Yamagami S, Miyazaki D, Ono SJ, Dana MR. Chemokine expression of allograft rejection in orthotopic mouse corneal transplantation. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S253.
40. Krenzer KL, Cermak JM, Tolls DB, Papas AS, Dana MR, Sullivan DA. Comparative signs and symptoms of dry eye in primary and secondary Sjögren’s Syndrome and Meibomian Gland Disease. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S542.
41. Sullivan DA, Papas AS, Stack KM, Stutz DJ, Dana MR, Cermak JM. Nutrient intake in women with primary and secondary Sjögren’s Syndrome. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S543.
42. Taylor AW, Block-Michel E, Dana MR, Labetoulle M, Streilein JW. Human uveitic aqueous humor is still immunosuppressive. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S592.
43. Zhu SN, Yamada J, Dana MR. ICAM-I is necessary for early host sensitization to donor MHC alloantigens in corneal transplantation. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S971.
44. Cermak JM, Krenzer KL, Dana MR, Sullivan DA. Do individuals with complete androgen insensitivity display the signs and symptoms of dry eye? Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S543.
45. Dekaris I, Dana MR. Topical soluble necrosis factor receptor I (sTNFRI) promotes the survival and decreases vascularization of minor alloantigen disparate corneal transplants. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S971.
46. Sullivan BD, Evans JE, Krenzer KL, Ullman MD, Dana MR, Sullivan DA. Influence of androgen deficiency on the fatty acid profile of neutral lipids in human meibomian gland secretions. Invest. Ophthalmol. Vis. Sci. 1999; 40 (Suppl): S980.
47. Dekaris I, Dana MR. Promotion of corneal graft survival by topical treatment with soluble tumor necrosis factor-alpha receptor I (sTNFR-I). Transactions of the European Society of Ophthalmology, 1999: 78.
48. Sullivan DA, Papas AS, Stack KM, Dana MR, Cermak JM. Nutrient intake in women with Sjögren’s Syndrome. Cl Exp Rheum 2000; 18.
49. Sullivan BD, Krenzer KL, Cermak JM, Dana MR, Sullivan DA. Effects of androgen deficiency on the lipid profile in human gland secretions. Cl Exp Rheum 2000; 18.
50. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Prevalence of dry eye syndrome in men and women, and its relationship with hormone replacement therapy in women. Cl Exp Rheum 2000; 18.
51. Dana MR, Balaram M. Efficacy and tolerability outcomes after silicone punctal occlusion in dry eye syndromes. Cl Exp Rheum 2000; 18.
52. Sullivan, DA, Krenzer KL, Tolls DB, Papas AS, Dana MR, Cermak JM. Are dry eye signs and symptoms different between Sjögren’s Syndrome and Meibomian Gland Disease? Cl Exp Rheum 2000; 18.
53. Yamagami S, Dana MR. Role of cervical lymph nodes in corneal allograft rejection. Transactions of the 16th Corneal Transplantation Meeting, Chiba, Japan, Feb. 2000: 75.
54. Khadem J, Tsao K, Hamblin M, Goslee M, Tolentino F, Dana MR. Photodynamic biologic tissue glue modulates rat corneal wound healing. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S700.
55. Sullivan DA, Belanger A, Cermak JM, Papas AS, Sullivan RM, Yamagami H, Dana MR, Labrie F. Are women with Sjögren’s syndrome androgen deficient? Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S276.
56. Yamagami S, Miyamoto K, Dana MR. Role of chemokines and chemokine receptors in corneal Langerhans cell migration. Transactions of the 104th Japanese Ophthalmological Society Meeting, April 2000, Kyoto, Japan: 129.
57. Sullivan BD, Dana MR, Sullivan DA. Impact of androgen deficiency on lipid profiles in human meibomian gland secretions. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S277.
58. Balaram M, Dana MR. Outcomes of phacoemulsification cataract extraction and posterior chamber lens implantation after allogeneic bone marrow transplantation. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S481.
59. Qian Y. Dana MR. Blockade of CD40-CD40 ligand pathway promotes survival of allogeneic corneal transplants. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S543.
60. Dana MR, Liu Y, Taylor AW. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor-derived antigens. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S543.
61. Liu Y, Taylor AW, Dana MR. Corneal allografts activate draining lymph node antigen-presenting cells. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S666.
62. Yamagami S, Dana MR. Role of cervical lymph nodes in corneal allograft rejection. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S667.
63. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Hormone replacement therapy (HRT) and the prevalence of dry eye symptoms. Invest. Ophthalmol. Vis. Sci. 2000; 41 (Suppl): S740.
64. Boisgerault FC, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G. Characterization of the T cell alloresponse in a fully mismatched murine model of corneal transplantation. Invest Ophthalmol. Vis Sci. 2000; 41 (Suppl): S667.
65. Miyamoto K, Yamagami S, Dana MR, Taylor AW, Ksander BR. Fas ligand on cornea endothelial cells triggers neutrophils to release MIP-2 chemokine. Ophthalmol. Vis Sci. 2000; 41 (Suppl): S117.
66. Schaumberg DA, Sullivan DA, Dana MR. The relationship of hormone replacement therapy to the prevalence of dry eye syndrome in a large cohort of women. Ophthalmology 2000; 107 (Suppl.): 105.
67. Balaram M, Dana MR. Cataract surgery in bone marrow transplant recipients with severe ocular surface disease. Ophthalmology 2000; 107 (Suppl.): 196.
68. Hamrah P, Zhang Q, Dana MR. Novel characterization of resident antigen-presenting cells in the corneal stroma. 2000 Annual OMIG Meeting Abstracts: 15.
69. Dana MR. Influence of cytokines, chemokines, and immunoactive agents in corneal and ocular surface immunity and inflammation. Cornea 2000; 19 (Suppl): S82.
70. Hamrah P, Zhang Q, Dana MR. Expression of vascular endothelial growth factor receptor-3 (vegfr-3) in the conjunctiva. Cornea 2000; 19 (Suppl): S93.
71. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Cornea 2000; 19 (Suppl): S120.
72. Sullivan RM, Cermak JM, Papas AS, Dana MR, Sullivan DA. Economic and quality of life impact of dry eye symptoms in women with Sjögren’s Syndrome. Cornea 2000; 19 (Suppl): S127.
73. Sullivan BD, Cermak JM, Sullivan RM, Papas AS, Evans JE, Dana MR, Sullivan DA. Correlations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren’s Syndrome. Cornea 2000; 19 (Suppl): S127.
74. Sullivan BD, Evans JE, Dana MR, Sullivan DA. Impact of androgen deficiency on the lipid profiles in human meibomian gland secretions. Cornea 2000; 19 (Suppl): S128.
75. Sullivan DA, Yamagami H, Liu M, Suzuki T, Krenzer KL, Cermak JM, Sullivan RM, Richards S, Schirra F, Dana MR, Sullivan BD. Sex steroids, the meibomian gland and evaporative dry eye. Cornea 2000; 19 (Suppl): S128.
76. Yamagami S, Hamrah P, Liu Ying, Dana MR. Role of chemokine receptors in corneal allograft rejection. Transactions of the 17th Corneal Transplantation Meeting, Osaka, Japan, Feb. 2001: 26.
77. Sakai R, Yamagami S, Tsuru T, Kawamoto S, Okubo K, Kinouchi T, Hamamoto T, Dana MR. A construction of human corneal endothelial cDNA library and identification of novel and active genes. 25th Corneal Conference, Osaka, Japan, Feb. 2001: 31
78. Yamagami S, Miyamoto K, Hamrah P, Miyazaki D, Dana MR. Role of CC chemokines and chemokine receptors in corneal Langerhans cell migration. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S575.
79. Sullivan BD, Dana MR, Sullivan DA. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S39.
80. Balaram, M, Dana MR. Ophthalmic complications after allogeneic bone marrow transplantation (allo-BMT). Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S66.
81. Sakai R, Yamagam S, Tsuru T, Kinouchi T, Hamamoto T, Dana MR, Kawamoto S, Okubo K. Construction of human corneal endothelial cDNA library and identification of novel and active genes. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S273.
82. Dana MR. Immunomodulation in corneal alloimmunity and inflammation. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S324.
83. Hamrah P, Zhang Q, Dana MR. The cornea, an immune privileged tissue, is endowed with significant numbers of resident MHC class II-negative dendritic cells. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S470. (winner of the Ocular Surface Society Best Presentation at 2001 ARVO meeting)
84. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Donor bone marrow-derived antigen-presenting cells (APC) traffic to draining lymph nodes after corneal transplantation. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S470. (winner of the 2001 Cora Verhagen Prize for the best presentation in immunology at the 2001 ARVO meeting)
85. Qian Y, Hamrah P, Boisgerault F, Yamagami S, Benichou G, Dana MR. Blockade of CD40-CD154 costimulatory pathway supresses graft rejection, ocular chemokine gene expression, and TH1 cytokine production in high-risk corneal transplantation. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S470.
86. Vora SR, Hamrah P, Yamagami S, Liu Y, Zhang Q, Dana MR. The chemokine receptor CCR1 mediates corneal allorejection. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S470.
87. Argüeso P, Balaram M, Spurr-Michaud S, Dana MR, Gipson I. Decreased levels of the gel-forming mucin MUC5AC in tears of sjögren’s syndrome patients. Invest. Ophthalmol. Vis. Sci. 2001; 42 (Suppl): S488.
88. Hamrah P, Liu Y, Yamagami S, Zhang Q, Dana MR. Targeting the chemokine receptor CCR1 suppresses corneal alloimmunity and promotes allograft survival. Cl Immunol 2001; 99: 118.
89. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Donor mone marrow-derived antigen-presenting cells traffic to draining lymph nodes after corneal transplantation. Cl Immunol 2001; 99: 125.
90. Qian Y, Leong F, Kazalauskas A, Dana MR. Ex vivo adenovirus-mediated gene transfer to corneal graft endothelial cells in mice. ARVO abstract 2002; 3193: 129.
91. Liu Y, Hamrah P, Taylor AW, Dana MR. Resident corneal dendritic cells that migrate from corneal explants may mediate alloreactivity. ARVO abstract 2002; 2264: 91.
92. Chen L, Hamrah P, Zhang Q, Dana MR. VEGFR-3 in cornea lymphangiogenesis and APC trafficking. ARVO abstract 2002; 2268: 91.
93. Huq SO, Liu Y, Illigens B, Qian Y, Benichou G, Dana MR. Direct pathway of allosensitization plays a significant role in high risk corneal transplantation. ARVO abstract 2002; 2275: 91.
94. Hamrah P, Haskova Z, Zhang Q, Taylor AW, Ksander B. Dana MR. Treatment with alpha-MSH reduces corneal allorejection. ARVO abstract 2002; 2961: 119.
95. Mendes F, Schaumberg DA, Navon S, Steinert R, Sugar J, Holland E, Dana MR. Quality of life assessment after corneal transplantation. ARVO abstract 2002; 3069: 124.
96. Schaumberg DA, Mendes F, Balaram M, Dana MR, Sparrow D, Hu H. Chronic low-level lead exposure and risk of cataract. ARVO abstract 2002; 935: 38.
97. Liu Y, Taylor AW, Dana MR. Corneal dendritic cells that migrate from corneal explants can mediate alloreactivity. Cl Immunol 2002; 103: S14.
98. Chen L, Hamrah P, Zhang Q, Dana MR. Role of VEGFR-3/Flt-4 in corneal lymphangiogenesis and APC trafficking. Cl Immunol 2002; 103: S16-17.
99. Sood A, Argueso P, Michaud S, Tisdale A, Gipson IK, Dana MR. Detection of Chemokine Receptor CCR5 on Conjunctival Epithelial Cells in Keratocojunctivitis Sicca. ARVO abstract 2003; 671.
100. Chen L, Hamrah P, Cursiefen C, Zhang Q, Streilein JW, Dana, MR. Role of VEGFR-3 on Corneal Lymphatic Drainage Antigen-Presenting Cell Trafficking and Alloimmunity. ARVO abstract 2003; 701.
101. Hamrah P, Liu Y, Zhang Q, Dana M.R.. Phenotypic Changes in Resident Corneal Dendritic Cells in Response to Inflammation. ARVO abstract 2003; 705.
102. Ohta K, Yamagami S, Wiggert B, Dana MR., Streilein JW. Chemokine Gene Expression in Iris-cilliary Body During Experimental Autoimmune Uveoretinitis. ARVO abstract 2003; 726.
103. Trivedi KA, Dana MR., Gilbard JP, Buring JE, Schaumberg DA. Dietary Omega-3 Fatty Acid Intake and Risk of Clinically Diagnosed Dry Eye Syndrome in Women. ARVO abstract 2003; 811.
104. Evans JE, Green KM, Sullivan RM, Schaumberg DA, Dana MR, Sullivan DA. Proteomic Analysis of Human Meibomian Gland Secretions. ARVO abstract 2003; 2478.
105. Huq SO, Illigens B, Benichou G, Dana MR. Director Pathway of Allosensitization- A Critical Pathway of Graft Rejection in High Risk Corneal Transplantation. ARVO abstract 2003; 3211.
106. Liu Y, Chen L, Taylor AW, Dana MR. Bilateral Allogeneic Corneal Transplantation: Corneal Tissue Antigens as Factors in Graft Rejection. ARVO abstract 2003; 3212.
107. Cursiefen C, Chen L, Jackson D, Rudge J, Wiegand S, Dana MR, Streilein JW. Complete Inhibition of Simultaneous Onset Corneal Lymphangiogenesis and Angiogenesis by Trapping Vascular Endothelial Growth Factor (VEGF) Using a VEGF Receptor 1 and 2 Chimeric Protein (VEGF Trap R1R2) ARVO abstract 2003; 3214.
108. Beauregard C, Dana MR, Capase Activation and Apoptosis in the Inflamed and Transplanted Cornea. ARVO abstract 2003: 4282.

Comments to: vision_training@vision.eri.harvard.edu
Last updated: March 3, 2004